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1. General Introduction and Objectives of the Thesis 
1.1 Introduction 
During the last 35 years protein pharmaceuticals have become more and more 
important. Protein pharmaceuticals belong to the group of biotechnologically 
produced pharmaceuticals; biotechnology uses living systems and organisms to 
generate pharmaceutical products. Biopharmaceuticals, such as proteins or peptides, 
offered millions of people hope to cure diseases like diabetes, cancer or immune 
mediated diseases. About 30 years ago, the first biosynthetically produced human 
protein was approved by Eli Lilly and company: recombinant human insulin (Humulin). 
During the following years, the manufacturing processes were substantially improved 
and other recombinant therapeutic proteins such as antibodies were developed. In 
2008, 633 biotechnological molecules were in development and today, numerous 
biopharmaceuticals have already gained approval. 
The outstanding advantage of biopharmaceutical therapeutics is the specific effect of 
the proteins on a certain target. Side effects, often occurring during therapies with 
small molecules, are minimized. 
Biopharmaceuticals are usually administered parenterally due to their poor 
bioavailability after application by most other administration routes. Proteins are not 
resistant against enzymatic and hydrolytic degradation in the gastrointestinal tract, 
further the protein molecules are too large to be resorbed during gastrointestinal 
passage. Protein pharmaceuticals have physical and chemical properties that imply 
difficulties in development, formulation, storage and shipping e.g. denaturation or 
aggregation. Maintaining stability is most crucial during the life-cycle of a therapeutic 
protein drug. This includes numerous steps, such as purification, formulation, storage 
and handling of protein drugs. Special care has to be taken during handling to avoid 
stress on the proteins and subsequent aggregation.  
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1.2 Protein instability  
Protein instability can result in loss of native molecules and thus efficacy of the drug. 
Especially aggregation is a well-known instability that occurs and might lead to 
immunogenic side effects or blood vessel occlusions [Rosenberg, 2006; Schellekens, 
2003]. Therefore, such instabilities have to be prevented to the utmost possible 
extent, which is a challenging task for drug development and manufacturing since the 
protein is exposed to numerous stress factors and changes in the environmental 
conditions that might destabilize the weak structure. In literature, proteins instability is 
subdivided into physical and chemical instabilities [Frokjaer et al., 2005; Lai et al., 
1999; Manning et al., 1989]. However, a protein can also undergo both classes of 
instability at the same time during purification, separation, manufacturing or storage.  
1.2.1 Chemical instability 
Proteins can be affected by different chemical reactions like deamidation, oxidation, 
proteolysis or hydrolysis. Chemical reactions result in strong structural changes of the 
protein e.g. the formation of new or release of existing covalent or non-covalent 
bonds or other decomposition reactions. 
Hydrolysis and oxidation of protein’s amino acids can lead to deamidation [Brange et 
al., 1992; Li et al., 1995; Reubsaet et al., 1998a] of side-chain amides (asparagine, 
glutamine) or degradation of asparagine and proline. 
Oxidation is a second pathway for chemical degradation, which results in modification 
of the protein by bond formation. Most susceptible amino acids are those that contain 
a sulphur or an aromatic ring such as cysteine or tyrosine [Stadtman, 1992]. 
Oxidation can be triggered by metals, oxygen, light and oxidizing-agents. Well-known 
is the oxidation in the presence of Fe(III) or Cu(II) [Tleugabulova et al., 1999; Wu et 
al., 2008]. Photooxidation may occur during processing or storage, protein 
pharmaceuticals are susceptible to light. Autoxidation is the reaction between 
molecular oxygen and the compound in absence of any catalytic process [Donbrow 
et al., 1978].  
To prevent oxidation reactions in therapeutic protein formulations either physical or 
chemical procedures can be conducted.  
 3 
Lyophilization can be used to prevent oxidation by physical means. The reduced 
mobility and the lack of solvent have been shown to prevent oxidation in a freeze-
dried cake [Jennings et al., 1995]. To chemically prevent oxidation, additives like 
chelating agents and antioxidants can be added to the formulation [Wang, 2000]. 
Further chemical degradation pathways that have been shown to occur in therapeutic 
proteins are for example ß-elimination reactions, disulphide exchange reactions and 
racemisation. Wang et al. provided summarizing literature on chemical stability of 
proteins [Wang et al., 2007; Wang et al., 2010]. 
1.2.2 Physical instability 
Proteins possess higher order structures (primary, secondary, tertiary) and a three-
dimensional conformation, required for biological activity. The primary structure 
describes the sequences of amino acids; the structure resulting from hydrogen bonds 
is defined as secondary structure. Such intermolecular bonding leads, for example, to 
α-helices and ß-sheet folding. The tertiary structure refers to the three-dimensional 
structure of a single protein molecule, driven by non-specific hydrophobic interactions 
(burial of hydrophobic residues in the protein core) and specific interactions like salt 
bridges and disulfide bonds.  
Physical instability refers to unfolding of protein’s native structure. In general, native 
and normally folded structures of proteins bury the hydrophobic groups. The native 
protein formation is preserved by many forces, such as hydrophobic and electrostatic 
interactions, hydrogen bonding and van der Waals forces [Dill, 1990]. The loss of the 
native structure is referred to as protein denaturation, which often leads to the 
formation of aggregates. Once unfolded, hydrophobic groups are exposed to the 
usually hydrophilic environment. In order to minimize free energy, the proteins tend to 
associate to hydrophobic surfaces and/or interact with other hydrophobic protein 
surfaces forming aggregates [Manning et al., 1989; Manning et al., 2010].  
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Fig. 1: Simplified model of protein aggregation and association [Wang et al., 2010] 
 
The native protein can reversibly unfold to an intermediate state [Reubsaet et al., 
1998b], that is also often referred as molten globule [Bam et al., 1996; Brange, 2000; 
Goolcharran et al., 2000]. Most protein aggregates are built from such partially 
unfolded intermediates [Andrews et al., 2007; Liu et al., 2008], which exist in 
equilibrium with the native state [Frokjaer et al., 2005]. A minor change in the 
environmental conditions, such as pH or temperature alterations, can shift the 
equilibrium toward the unfolding intermediates. The intermediate state is usually 
thermodynamically unstable and thus can either enhance the protein’s tendency to  
aggregate [Krishnan et al., 2002] or lead to complete unfolding of the protein, 
resulting in denaturation. Protein molecules of each conformational state (native 
[Roberts, 2007], molten globule, and modified or denatured [Krishnan et al., 2002]) 
can be involved in self-association leading to aggregation and precipitation (figure 1). 
The refolding of the intermediate to the native state exists in an equilibrium state; 
hence refolding in a certain percentage is given. However, in some cases, such as 
high pressure, the equilibrium can be shifted preferring the native state [Zhang et al., 
1995].  
Aggregation can result from many protein destabilizing factors, such as mechanical 
or thermal stress. Aggregates can be classified in numerous ways, such as 
soluble/insoluble, non-covalent/covalent, reversible/irreversible or native/denatured 
[Cromwell et al., 2006].  
Insoluble aggregates are removable by filtration through 0.22 µm filters. Insoluble 
aggregates can be further subdivided into visible and subvisible aggregates. 
Aggregates ≤1 µm often are referred to as subvisibles, whereas aggregates ≥1 µm 
are referred to as visible aggregates [Carpenter et al., 2008; Narhi et al., 2011]. 
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Soluble aggregates can be defined as aggregates not removable by a 0.22 µm filter 
[Cromwell et al., 2006].   
Covalent aggregates between two monomers can be formed via disulfide bridges 
between sulphur-residues of amino acids such as cysteine. Non-covalent aggregates 
have weak interactions, such as hydrogen bonding or electrostatic forces [Demeule 
et al., 2007].  
Non-covalent weak interactions often result in reversible aggregates. The formation 
of reversible aggregates is considered to be caused by self-association as a result of 
pH-shift or changes in ionic strengths [Kendrick et al., 1998]. In case of reversible 
aggregation an equilibrium between aggregates and native protein exists, whereas 
irreversible aggregates do not have the equilibrium with monomer. 
Native aggregates are referred to as aggregates with remaining native protein 
structure. Structural changes within proteins lead to denatured aggregates [Chi et al., 
2003]. 
1.2.3 Factors that affect protein stability 
Chemical and physical protein instability and subsequent aggregation can be caused 
by various stress factors, such as elevated temperatures, exposure to light [Kerwin et 
al., 2007] and interfaces [Bee et al., 2009a; Bee et al., 2010], agitation [Eppler et al., 
2010; Maa et al., 1996], freeze-thawing [Bhatnagar et al., 2007] or impurities [Chi et 
al., 2005; Jones et al., 2005; Thirumangalathu et al., 2009; Tyagi et al., 2008; Van 
Beers et al., 2012]. The most important and further elaborated factors are thermal 
and mechanical stress, as well as freeze-thawing. 
Temperature is a critical parameter for storage and use of protein therapeutics since 
the stability of proteins is even at physiological temperature weak [Brange, 2000]. 
Elevated temperatures can cause unfolding of the protein. Such conditions can 
induce unfolding which leads to reduction of ß-sheet and ß-turn conformations in 
protein structure and simultaneously increase the amount of α-helices [Vermeer et al., 
1998]. These changes can subsequently even cause protein denaturation [Chen et 
al., 1994; Hawe et al., 2009]. In general protein stability is increasingly reduced with 
higher temperatures. Formation of aggregates due to thermal stress has been 
investigated for many proteins, such as antibodies [Harn et al., 2007; Hawe et al., 
2009], human serum albumin [Lin et al., 2009] and insulin [Singh et al., 1991].  
Several studies have investigated the thermal stability of proteins with regards to 
concomitant stress factors. Treuheit et al. showed that heat induced unfolding and 
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the resulting aggregation of e.g. GCSF increased at high protein concentrations 
[Treuheit et al., 2002]. For Interferon-τ it was reported that the composition of 
formulation buffer can have a profound effect on the thermal stability [Katayama et al., 
2006].  
Another factor that can impact protein stability is agitation. Mechanical stresses a 
protein can be exposed to during production and handling are shaking and stirring. 
Agitation of protein solutions can lead to the creation of new air-water interfaces. 
These interfaces can lead to protein unfolding and aggregation. Proteins are surface 
active substances and thus able to adsorb to the new formed air-water-interfaces 
[Burke et al., 1992]. The protein tends to unfold its hydrophobic cores and interact 
with or attach to hydrophobic air surfaces. Hydrophobic interactions between proteins 
are likely [Privalov et al., 1988]. Therefore the headspace in primary packaging 
materials is an important parameter. A large headspace usually increases the 
protein’s tendency to form aggregates [Kiese et al., 2008]. Aggregation caused by 
mechanical stress has been reported for many proteins, such as monoclonal 
antibodies [Bee et al., 2009b] and haemoglobin [Kerwin et al., 1999]. 
Freeze-thawing is the last factor that should be mentioned in this context. Freeze-
thawing exerts different stresses on the protein. It has been reported that freezing 
rate and control of thawing influences the rate of protein aggregation [Cao et al., 
2003]. Aggregation upon freeze-thawing is reported of antibodies [Hawe et al., 2009] 
or human growth hormone [Eckhardt et al., 1991]. Privalov et al. reported that low 
temperature can cause unfolding due to favourable hydration of non-polar groups 
within the protein [Privalov, 1990]. The exposure of non-polar groups to water is 
thermodynamically unstable and thus aggregation or adsorption to hydrophobic 
surfaces or interfaces [Kreilgaard et al., 1998; Strambini et al., 1996] can occur. 
During freezing, crystallisation of the solvent molecules occurs resulting in increasing 
concentrations of protein and excipients in the remaining solution. Hence, 
aggregation can for example be caused by high protein concentration, imbalance of 
stabilizing and destabilizing agents and/or pH-shifts due to water removal. Proteins, 
such as antibodies, have been shown to be instable at low pH [Ejima et al., 2007], 
that can be generated during freezing of a phosphate buffer formulation [Pikal-
Cleland et al., 2000].  
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1.3 Analytical methods for stability assessment of therapeutical 
protein formulations 
To date, many analytical techniques have been developed to assess the stability of 
proteins. These analytical techniques are dedicated to give information on protein 
denaturation and aggregation or conformational and structural changes. 
As mentioned above aggregates can strongly differ in size. Unfortunately, one single 
method covering the whole size spectrum in aggregate detection does not exist [Philo, 
2006]. Hence, scientists and pharmaceutical companies have to use orthogonal 
techniques to characterize protein aggregates. Numerous different methods for 
aggregate detection are already well-established. 
For our studies, mainly methods to quantify protein aggregates were used. To give a 
broad overview and for the sake of completeness, not only applied methods are 
described within this chapter but also those quantification methods that are found to 
be important. A comprehensive collection of literature regarding analytical methods is 
summarized [Zoells et al., 2011]. 
 
 
Fig. 2: Aggregate quantifying and sizing methods and their detection limits; DLS (Dynamic Light 
Scattering), SEC (Size Exclusion Chromatography), AUC (Analytical Ultra Centrifugation), AF4 
(Asymmetrical flow field-flow fractionation), LO (Light obscuration), MFI (Microflow Imaging), ESZ 
(Electrical Sensing Zone). Figure adapted from presentation Klaus Zwiorek, Sanofi, July 11
th
 2007. 
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Figure 2 gives an overview which methods can be applied to determine the amount 
and size of protein aggregates. The detection sizes reflected in this figure show the 
ranges where a reliable quantification of aggregates can be obtained by each method.  
1.3.1 Light scattering 
Dynamic Light Scattering (DLS) 
In DLS, which is also referred to as photon correlation spectroscopy (PCS) or quasi 
elastic light scattering (QELS), intensity fluctuations of scattered light are measured. 
Depending on their size, particles in suspension undergo Brownian motion [Malvern, 
2007]. The intensity of scattered light is size dependent, smaller particles move more 
rapidly [Ahrer et al., 2003]. Therefore, the time dependent fluctuations are a rate of 
the diffusion constant of the molecules and are related to the hydrodynamic diameter 
of a molecule [Jachimska et al., 2008]. Possibly existing protein aggregates within the 
protein solutions can be considered as suspensions. For non-interacting rigid 
spheres (ideal solutions) the hydrodynamic radius is defined by the Stokes-Einstein 
equation [Demeester et al., 2005] as:  
D
Tk
r Bh
6
  
Where kB is the Boltzmann’s constant, T is the absolute temperature, η is the solvent 
viscosity and Dτ is the diffusion coefficient [Jiskoot et al., 1990]. Only extremely 
diluted solutions without interactions can be accounted as ideal, and are in general 
not existent in the field of protein formulations. Instead, proteins form non-ideal 
solutions. 
Non ideal solutions are defined as solutions where protein interactions occur. In non 
ideal solutions, which occur practically, DLS measures the mutual diffusion coefficient 
Dm, which varies with protein concentration: 
)1( pDm ckDD    
Where kD is a factor of interparticle action and cp is the protein concentration. 
DLS measurements provide information about the molecules respective the protein 
aggregates hydrodynamic radius, which is the radius of the molecule and its 
hydration layer.  
DLS analytics need low effort in sample preparation, since proteins in solution can 
theoretically be analyzed without dilution. Furthermore, DLS platereaders enable 
high-throughput measurements of many samples in several minutes. However, a 
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drawback of the method is its susceptibility to interfering scattering effects deriving 
from air bubbles, dust and large aggregates or turbidity [Mahler et al., 2008].  
 
Static Light Scattering (SLS) 
In SLS, the scattered light intensity is measured as a function of the angle between 
detector and the incident laser beam direction. SLS measurements give information 
concerning molar mass, molecular root mean square radius, conformation, and 
intermolecular interactions [Minton, 2007]. However, small changes in molecular 
weight (e.g. protein deamidation) can not be detected [Demeester et al., 2005]. Static 
light scattering measurement at various angles is called multi-angle light scattering 
(MALS) [Andersson et al., 2003]. MALS determines the angular dependence of 
scattered light and thus enables the direct calculation of molecular sizes. It is very 
common to connect a MALS-detector to a separation technique to supplement the 
detection with UV detector. Using the combination SEC-MALS [Philo, 2006; Wen et 
al., 1996; Ye, 2006], molecular mass and small aggregate concentrations can be 
determined [Mahler et al., 2008].    
1.3.2 Chromatography 
Chromatographic methods are used for separating molecules. Separation is based 
on interactions of molecules with a mobile and a stationary phase. Molecules in the 
mobile phase travel with a constant speed down the chromatographic column or 
carrier material. The speed molecules travel with depends on their affinity for the 
stationary phase. 
A common chromatographic method in the field of protein analysis is Size Exclusion 
Chromatography (SEC), often referred to as gel filtration. The separation principle 
relies on the different sizes respectively hydrodynamic volumes of proteins relative to 
a given pore diameter of the stationary phase [Gabrielson et al., 2007]. Ideally, there 
should be no interaction between the proteins and the stationary phase [Bischoff et 
al., 2005], but usually this is not the case.  
In protein analytics Size Exclusion Chromatography (SEC) can give useful 
information about fragments, monomer- and small oligomer content. Protein 
aggregates, fragments and monomer are eluted depending on their sizes; the larger 
the protein aggregates the earlier they are diluted as they can not penetrate into the 
pores of the gel. The size of protein particles that can be determined by SEC is 
restricted to ~200 nm diameter, as usually a 0.2 µm filter prevent larger particles from 
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entering and clogging the column. If aggregates are too large, they are directly eluted 
with the mobile phase without penetrating into pores of the gel [Mahler et al., 2008]. 
Therefore, the relevant detection range of SEC was defined as 1-200 nm (see figure 
2).  
By recalculating the recovery in a given sample assumptions on the amount of 
aggregates >200 nm can be made. Aggregates >200 nm are given as a percentage 
of total protein. However, conclusions regarding size of those aggregates are not 
possible.  
Separation can be coupled with detectors such as UV-Vis (ultraviolet-visible) or 
fluorescence spectroscopy detectors, which offer information about the aggregate 
concentrations. Further, separation can also be coupled with light scattering 
detectors to determine the molar mass [Philo, 2006; Ye, 2006]. Further, an additional 
refractive index detector delivers useful information on the aggregates’ sizes [Wen et 
al., 1996]. 
Disadvantageously, samples analyzed by SEC are highly diluted by the mobile phase 
and can also interact with the stationary phase. In both cases the result might be 
adulterated due to conformational changes of the protein molecules [Wen et al., 
1996] or dissolution of aggregates [Liu et al., 2006; Philo, 2006]. 
1.3.3 Analytical ultracentrifugation (AUC) 
AUC is one of the eldest methods for characterization of protein’s solution structure 
and conformation [Liu et al., 2006; Wandrey et al., 2011]. The instrument is 
composed of a high-speed centrifuge with an added optical system for measuring the 
distribution of different sized protein aggregates. Optical systems, that measure 
differences between protein sample and buffer, can be either absorbance systems 
(190-800 nm) or Raleigh interference systems measuring refractive index gradients 
[Philo, 2005]. Concentration distributions can be estimated based on physical 
properties [Chou et al., 2011]. AUC experiments can be further subdivided in 2 
methods determining different parameter of a sedimentation process:  
During a sedimentation velocity (SV) experiment the centrifuge is rotating at a very 
high speed (up to 60.000 rpm) implying that all protein molecules to be driven 
completely to the wall within a few hours. Different protein species, such as the 
monomer and aggregates, sediment at their own rate and thus are separated, 
sediment can be distinguished from each other based on their varying sedimentation 
velocities. These rates for example depend on the one hand side on properties of the 
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protein to be analyzed like concentration, the sedimentation coefficient of the protein 
species, their molecular mass and conformation, and on the other hand side on 
solvent properties like viscosity and solvent density. Monitoring the sedimentation 
process of single molecules and agglomerates allows the determination of their 
hydrodynamic and thermodynamic characteristics in solution, without interaction with 
any matrix or surface [Lebowitz et al., 2002].  
A second option of performing AUC measurements is to monitor the sedimentation 
equilibrium of proteins which provides information about the respective molar mass 
and self-association of protein species as well as heterogeneous interactions as soon 
as an the equilibrium of protein species in solution upon centrifugation is reached 
[Mahler et al., 2008]. At a low rotor speed the macromolecules diffuse to the outside 
of the rotor until a steady-state is reached [Philo, 2009]. Smaller particles move and 
diffuse more rapidly to the outside than larger particles.   
Both AUC methods do not rely on protein standards and can be performed in 
formulation buffers [Philo, 2005]. However, experienced staff is needed due to 
complex and tedious validation, instrumentation, and data analysis [Liu et al., 2006]. 
Disadvantageously, both methods have a very low throughput rate of maximum 
seven samples per day.  
1.3.4 Asymmetrical flow field-flow fractionation (AF4) 
Asymmetrical flow field-flow fractionation is another widely used technique to detect 
and quantify protein aggregates [Mahler et al., 2008]. Instead of separation in a 
column packed with solid material like in SEC, AF4 relies on separation in a channel 
of defined height. The channel is made of an upper impermeable wall, a spacer 
defining channel height and shape, and a lower permeable channel wall [Fraunhofer 
et al., 2004]. The latter is permeable for the mobile phase and composed of an 
ultrafiltration membrane with a certain molecular weight cut-off to retain the analytes 
of interest placed on a frit. After injection to the channel and subsequent focussing or 
relaxation of the sample, the protein species are forced by a laminar forward flow of 
the mobile phase to pass the channel towards the detection outlet. The laminar flow 
profile entails a high velocity in the channel center and a low velocity at the channel 
walls. A perpendicular field of force (also called cross flow) is applied, that forces the 
protein species towards the accumulation wall. The cross flow is made of mobile 
phase as well and is able to permeate the ultrafiltration membrane and frit that form 
the lower channel wall. The antagonist of the cross flow is the size dependent 
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diffusion of the particles directed back to the channel interior. For small species 
diffusion predominates over cross flow and thus smaller particles are able to reach 
the center of the channel, whereas larger particles stay near the accumulation wall. 
Hence, smaller particles travel faster than larger particles and are therefore eluted 
earlier.  
Compared to SEC, the key benefits of AF4 are a more gentle fractionation at lower 
pressure. AF4 has a narrow flow channel which potentially reduces interactions of  
[Demeule et al., 2007; Liu et al., 2006]; SEC has a packed column posing interaction 
possibilities with the analytes. For AF4 separations, the fractionation force can be 
adjusted during one measurement and less sample preparation is required. SEC 
separations require sample preparation and online adjustment of fractionation is not 
possible [Philo, 2006]. Advantageously, AF4 detects protein particles up to 100 µm, 
whereas particles of such size would already be hindered by the frit to enter the SEC 
column. However, the resolution is not as sensitive as it is known for SEC. 
1.3.5 Particle counting  
Particle counting is a compendial requirement for parenteral solutions. Formation of 
particles is a major concern during development and manufacturing of protein 
pharmaceuticals. Particles can be differentiated into visible (>100 µm) and subvisible 
particles (0.1-100 µm) [Carpenter et al., 2008]. Detection and quantification of 
subvisible particles has to be performed with particle counters or microscopic 
methods, whereas visible particles can be seen with the unaided eye. 
Pharmacopoeias require the monitoring of particulate matter for particles ≥10 µm and 
≥25 µm in parenteral solutions. Preparations supplied in containers with a volume of 
more than 100 ml must not obtain more than 25 particles/ml ≥10 µm and 3 particles 
≥25 µm. The requirements for preparations supplied in containers with a volume of 
25 – 100 ml are as follows: particle counts for particles ≥10 µm must not exceed 
6000 per container; particle counts for particles ≥25 µm must not exceed 600 per 
container [European Directorate For The Quality of Medicine (EDQM), 2011; United 
States Pharmacopeia, 2009]. The relevance of those numbers and the need to 
determine particulate matter <10 µm is currently discussed in the scientific 
community [Cao et al., 2009; Carpenter et al., 2008; Singh et al., 2010].  
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1.3.5.1 Light obscuration 
Light obscuration (LO, also called light blockage) instruments with a detection range 
from 1 µm to 100 µm or more are the most commonly used instruments for 
quantification of subvisible particles and are described in the pharmacopoeias as 
method of choice for determination of particulate matter. The particle size is deduced 
from the amount of light blocked as the particles pass the detector in a single file 
fashion [Mahler et al., 2008].  
Artificial and even irreproducible [Cao et al., 2010] results may occur at high protein 
particle concentrations, when detection limit is reached and the particles can not be 
counted anymore in single file fashion [Zoells et al., 2011]. If two or more particles 
pass the laser beam simultaneously, coincidence occurs. Particles could either be 
not detected, because particles are covering each other, or instead of detecting 
single small particles one large particle is detected. The pharmacopoeias require 
additional microscopic particle counting for preparations with particle counts 
exceeding the instruments limits, since dilution of samples can lead to redissolving of 
particles.  
Light obscuration instruments are calibrated with polystyrene standards of defined 
circular diameters and defined contrast in refractive index to the liquid. However, 
protein particles do not have defined shapes, refractive indices (RI) and sizes 
[Sharma et al., 2010a; Sharma et al., 2010b]. Protein particles can have a RI close to 
the solvent solution RI. Such low RI differences can lead to oversight of protein 
particles and subsequently false (too low) particle counts. 
False results can also be caused by particles of high transparency that cannot be 
detected by light obscuration [Demeule et al., 2010; Huang et al., 2008], since a 
sufficient contrast of particle and liquid is necessary. Thus, particle number and size 
can be underestimated. 
A further drawback is that LO instruments can not differentiate between 
proteinaceous and non-proteinaceous particles or air bubbles.  
The advantage of the LO principle is the fast and simple measurement and 
evaluation handling.  
1.3.5.2 Microscopic particle counting 
Microscopic particle counting on filters is described within the pharmacopoeias as an 
alternative method for particulate matter determination [European Directorate For 
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The Quality of Medicine (EDQM), 2011; United States Pharmacopeia, 2009]. The 
total particle numbers obtained from microscopic particle counting can not be 
compared with the results from compendial light obscuration due to different 
sensibilities [Demeule et al., 2010]. The acceptance criteria for microscoping particle 
counting by microscopy differ from those of light obscuration: Preparations supplied 
in containers with a volume of more than 100 ml should not obtain more than 12 
particles/ml ≥10 µm and 2 particles ≥25 µm. The requirements for preparations 
supplied in containers with a volume of 25 – 100 ml are as follows: particle counts for 
particles ≥10 µm must not exceed 3000 per container; particle counts for particles 
≥25 µm must not exceed 300 per container. 
Particle counting tests with a binocular microscope at 100 ± 10 magnifications are 
performed using an ocular micrometer. The ocular micrometer is equipped with a 
graticule and reference circles of 10 µm and 25 µm. The graticule is devided into 
quadrants by crosshairs [United States Pharmacopeia, 2009]. 
According to light obscuration method described above samples have to be pooled. 
The sample to be tested is transferred to a filtration funnel, and then a vacuum is 
applied until the membrane filter is free from liquid. The dried membrane filter is 
scanned under reflected light and particles ≥10 µm and ≥25 µm are counted. 
A clear drawback of microscopic particle counting is the manual operation. Sample 
preparation and particle counting is not automated, implicating the influence of the 
operator and human mistakes. Furthermore, microscopic particle counting is very 
time-consuming and not feasible for routine production or development processes. 
An advantage of this method is the possibility to determine particulate matter in highly 
contaminated solutions. As mentioned above it is even compendially required to test 
samples of particle counts exceeding the limits of light obscuration instruments with 
the microscopic particle counting test. 
1.3.5.3 Microflow Imaging (MFI) 
The Microflow Imaging technique to detect and count subvisible particles in the µm -
range has been developed during the last 10 years. It combines digital microscopy, 
micro-fluidics and image processing. Images from samples are captured when 
passing a laser beam in a flow cell. Microflow imaging analyzes each particle 
detected with regards to its size, transparency and shape. For each measurement a 
database is created, from which the particle properties can be recalled at any time. 
The databases can be used to attribute particles with defined properties to respective 
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origins. For example, circular particles in protein solution usually are silicone oil or air 
bubbles.  
The range of particle detection is dependent on the equipment from 750 nm or 1 µm 
to 200 µm.  
An outstanding advantage is the possibility to get information about shape and 
transparency of particles [Narhi et al., 2011; Sharma et al., 2007; Sharma et al., 
2010b; Sharma et al., 2010a]. With experience, detected particles can be attributed 
to respective origins, such as protein-related, air bubble, silicone oil or glass particles 
[Demeule et al., 2010; Sharma et al., 2009].  
A drawback of MFI is, similar to light obscuration, that highly contaminated protein 
solutions can not be measured without dilution of the sample due to the appearance 
of coincidences. Further MFI depends on differences in the refractive index difference 
of particles and liquids. This implicates that highly concentrated solutions or very 
transparent particles provide insufficient contrast from particle to liquid. However, the 
minimal difference in refractive required for successful MFI analysis is smaller than 
for classical light obscuration.  
1.3.5.4 AccuSizer FY nano 
The AccuSizer FY nano is also a new particle counting method developed by PSS 
Nicomp (Santa Barbara, CA, US) and emerged on the market about four years ago. 
The AccuSizer nominally counts particles in the range of 150 nm to 10 µm using two 
detectors [Nicomp, 2008]. When a particle passes the sensing zone, light is absorbed, 
reflected or scattered in an angle, dependent from particle size. A light scattering 
detector is counting particles in the nanometer range by sensing different intensities 
of scattered light which are related to defined sizes. Larger particles are counted by a 
light obscuration detector. 
Advantageously, the instrument dilutes the samples automatically with filtered water, 
until an eligible particle count is reached. Measuring sufficiently diluted samples 
ensures that the particles pass one at a time the illuminated region. Coincidences 
can be avoided. However, as mentioned before, dilution can also have an impact on 
protein aggregates and hence on the results. A focused extinction is used during 
measurements. Only a few particles flowing through the focus within the flow cell are 
counted. As for MFI, the particle count is recalculated to obtain the count per milliliter. 
Disadvantageously, particle counts can e.g. be underestimated [Demeule et al., 
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2010], if samples with very low particle counts are measured and randomly a fraction 
without particles is counted. The recalculation would lead to a biased particle count. 
The detection limit of the AccuSizer FY nano is very promising, as it closes the gap of 
quantitative particle detection in the nanometer size range. A rigorous assessment of 
the new AccuSizer FY nano has been performed throughout this thesis and is 
extensively discussed in chapter 3.  
1.3.5.5 Electrical sensing zone method 
This method is based on an electrical field for counting and sizing particles in 
solutions and is most commonly known as Coulter Counter® or Coulter principle. 
Particles moving in the electrical field cause an increase of the electrical resistance.  
Therefore, sufficiently diluted particles should be suspended in a conducting liquid to 
ensure an electrical current. The electrical current is changed by each particle 
proportional to the particles size as soon as a particle pass the electrical sensing 
zone.  
The electrical sensing zone principle can be compared to classic light obscuration as 
required within pharmacopoeia. Both methods deliver the information about particle 
size and particle count.  
The benefit of the Coulter principle is the detection of particles independent on their 
refractive index. As the Coulter principle is not relying on refractive index differences 
between particles and liquids, even less compact proteinaceous particles with low 
contrast to the liquid can be detected without any problems [Barnard et al., 2012; 
Rhyner, 2011]. Further, particulate matter in highly concentrated solutions with a high 
refractive index and respective low contrast between particle and liquid can be 
determined [Demeule et al., 2010]. A drawback of the electrical sensing zone is the 
requirement to dilute the particles into conducting liquids if the formulation buffer 
possesses sufficient conductivity.  
1.4  The compendial and analytical gap 
Strategies for stability assessment for protein formulations become more and more 
important [den Engelsman et al., 2011] for development and manufacturing of protein 
pharmaceutics. The authorities require increasingly more detailed investigations and 
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understanding of a protein’s quality (with special focus on particles) prior to approval.  
Regulatory frameworks regarding absence of particles and aggregates have to be 
very strict to assure protein safety, efficacy and stability [ICH Q8, 2009].  Quality by 
design is required to maximize protein quality. Therefore, predefined specifications 
“should focus on those molecular characteristics found to be useful in ensuring the 
safety and efficacy of the product” [ICH Q6B, 1999].  
During the last years, the scientific community has been discussing the need of 
implementing new pharmacopoeial methods, such as Microflow Imaging [Mire-Sluis 
et al., 2011], for counting protein particles. The bones of contention were guidelines 
regarding particulate matter in parenteral solutions. USP <788> stated that 
“Particulate matter consists of extraneous, mobile, undissolved substances, other 
than gas bubbles, unintentionally present in parenteral solutions”. Similarly, Ph.Eur. 
2.9.20 defined “Particulate contamination of injections and parenteral infusions 
consists of extraneous, mobile undissolved particles, other than gas bubbles, 
unintentionally present in the solutions”.  
Those guidelines have originally been set for small molecules and are not 
appropriate anymore in times when biologicals with high molecular weights play an 
important role on the market. Proteins themselves can contribute to significant 
colloidal particle counts, they tend to form aggregates; those can impact safety and 
efficacy. In 2007, USP, European Pharmacopoeia and Japanese Pharmacopoeia 
defined that “Particulate matter in injections and parenteral infusions consist of 
mobile undissolved particles, other than bubbles, unintentionally present in solutions” 
[United States Pharmacopeia, 2009]. This harmonization of definition for particulate 
matter includes protein aggregates as well as unintentionally extraneous present 
particles.  
After harmonization a new discussion was raised regarding the monitored particle 
size classes. Currently, monitoring of particles ≥10 µm and ≥25 µm is required and 
limits are defined. These size ranges are still leftovers from ancient guidelines and 
inadequate for protein pharmaceuticals nowadays. The limitation was defined 
because of the risk for blood vessel occlusions that can be triggered by particles 
>10 µm, whereas aggregates >10 µm and also <10 µm are discussed to cause 
immunogenic side effects [Barnard et al., 2010; Fradkin et al., 2009; Jiskoot et al., 
2009; Rosenberg, 2006; Schellekens, 2003]. Recently, it was reported in literature 
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that large insoluble aggregates of murine growth hormone generated by freeze-
thawing or agitating can induce immune responses [Fradkin et al., 2011]. 
In theory, protein aggregation starts with very small aggregates, called precursors or 
nuclei [Golub et al., 2007; Mahler et al., 2005], which can grow further forming larger 
aggregates. Therefore, it is discussed, whether the requirements to monitor only 
particles ≥10 µm and ≥25 µm are sensitive enough for protein pharmaceuticals. 
Protein particles might be in the subvisible range during release and to small to be 
detected. During storage growth of particles has to be considered, large protein 
particles might harm the patients after parenteral application of aggregated solutions. 
Many authors postulate a new pharmacopoeial method to monitor also subvisible 
particles in the range from 1 µm till 10 µm or even below.  
Besides the monitoring also an “equipment gap” for particle detection is discussed. 
One single method covering all possible instabilities and aggregate sizes does not 
exist [Das et al., 2008; Narhi et al., 2009; Philo, 2006]. As mentioned before, 
subvisible particles ≥10 µm are monitored and counted using classical light 
obscuration. This technique is not capable of counting particles smaller than 1 µm 
(figure 1). Aggregates <1 µm can be determined semi-quantitatively using light 
scattering or chromatographic methods. Each method comes with advantages and 
disadvantages and none can provide a complete overview on a product by its own. 
Thus, usually a variety of analytical methods complementing or being orthogonal to 
each other are used to characterize protein formulations. For each product it is 
important to close existing gaps in analytical equipment [Carpenter et al., 2008] to 
improve safety and efficacy. These gaps can include a certain size range, or for 
example can be caused by high translucency of the particles impacting detection by 
light based methods. Lately, a method independent on optical properties has been 
assessed regarding its ability to provide more information on protein aggregation in 
the subvisible size range [Barnard et al., 2012]. As the Coulter method does not 
depend on optical properties of particles, detection of translucent protein particles 
was unproblematic.  
 
Recently, new particle counters with additional beneficial read-out parameters 
emerged on the market. Microflow Imaging (MFI) possesses the add-on to visualize 
detected and counted particles. Information about shape or transparency of particles 
is provided, which allows differentiation between proteinaceous and non-
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proteinaceous particles [Sharma et al., 2009]. It has already been addressed in 
literature that MFI is more sensitive to translucent particles than classical light 
obscuration [Huang et al., 2008; Sharma et al., 2010b].  
AccuSizer nano FY is also a new particle counter with promising detection limit for 
particles from 150 nm to 10 µm, which would perfectly close the equipment gap for 
particle counting. 
Only recently brand-new technologies, such as Archimedes [Mire-Sluis et al., 2011] 
and nanoparticle tracking analysis (NTA) [Zoells et al., 2011], were discussed. 
Archimedes technology determines the mass of the submicron aggregates. NTA 
records the scattered light of individual moving protein particles and a software 
visualizes microscopic images. 
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1.5 Objective of the thesis 
The most important objective of the thesis was to evaluate new analytical instruments 
and techniques for counting particles within protein pharmaceuticals. AccuSizer FY 
nano® and Micro-Flow ImagingTM DPA 4200 were rigorously assessed regarding their 
abilities to deliver more information about protein aggregation and to close the gap in 
analytical techniques for determination of subvisible particles as described in 
literature [Carpenter et al., 2008]. For this purpose four different proteins were 
stressed mechanically, thermally and by freeze-thawing to generate aggregates. 
Sampling was performed at defined time points during stressing. Stressed samples 
were analyzed using the new particle counters and “standard” instruments, such as 
light obscuration, dynamic light scattering and size exclusion chromatography. 
Results of the measurements were evaluated to find the point of detection for each 
instrument, which is the time point, where stress results in measurable aggregation or 
e.g. decrease of monomer amount. To compare the new instruments with the 
classically used methods, time points of detection were compared. These 
comparisons deliver valuable information about the sensitivity of the instruments, the 
usefulness to implement such methods within the pharmacopoeia and the relevance 
of submicron particle counting. 
 
Further, this thesis is intended to elucidate the fate of protein particles after 
administration into serum solution. Much research has been done in the field of 
protein aggregation, however, most of it in vitro. The thesis aims to contribute to the 
raising discussion about the fate of proteins and their aggregates when administrated 
into human serum. Three different proteins were stressed mechanically, thermally 
and by freeze-thawing to generate aggregates. The aggregates were administered in 
a 1:50 dilution into serum solution and particle counts were taken after defined time 
points. It was of great interest, whether particles accumulate and grow or whether 
particles redissolve after administration. Further, the ability of particle counters to 
detect particles in yellowish serum solution was to be checked. 
Evaluating the effects of dilution, pH and standing time on particulate matter was 
defined as a sub-goal. An antibody was stressed mechanically and diluted into 
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phosphate buffers with different pH values and molarities. Particle counts were taken 
and assessed. Particles generated after lab stress might redissolve over time and if 
so, they are to be considered differently compared to those that do not redissolve. 
 
In the field of protein formulation development the discussion was raised, whether 
aggregation prediction during upscaling is possible. Protein formulators perform their 
experiments in the small lab scale. As soon as those experiments have to be scaled 
up, questions regarding e.g. stirring speed in the technical scale are posed. What 
correlations can be found between particle formation and stirring speed and is 
particle formation in a larger scale predictable? As aggregation prediction is not a 
common process, upscaling means to experimentally test the optimal stirring speed. 
The possibility of aggregation prediction would be an improvement and save time, 
money and active pharmaceutical ingredient (API). One objective of this thesis was to 
study and simulate the possibility of aggregation prediction with use of Computational 
fluid dynamics. 
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2. Material and Methods  
2.1 Materials 
2.1.1 Therapeutic proteins 
2.1.1.1 IgG1-α and IgG1-ß 
Two humanized monoclonal antibodies (Immunoglobulines) of the IgG1 class were 
used as model proteins. In order not to use the names of patented IgG1 and to 
distinguish them though, the immunoglobulines were named IgG1-α and IgG1-ß. 
Monoclonal antibodies are Y shaped and glycoproteins of the immune system [Wang 
et al., 2007]. There are five isotypes of immunoglobulines (Ig): IgA, IgD, IgE, IgG, IgM. 
The isotypes can be further differentiated into different subclasses. IgG is the most 
important group of immunoglobulines. Antibodies consist of two heavy and two light 
polypeptide chains, which are connected by two disulfide bonds. 
IgG1-α used in this thesis is formulated at 5.0 mg/ml in 10 mM histidine, 65 mM NaCl 
and 5 % sucrose at pH 6.0.  
IgG1-ß used is formulated at 10.3 mg/ml in 25 mM histidine, 250 mM glycine, 1% 
sucrose and 0.01 % polysorbate 80 at pH 5.8. For our studies the bulk was diluted to 
a concentration of 5.0 mg/ml. 
2.1.1.2 GCSF 
Granulocyte colony stimulating factor (GCSF) was used as the third model protein. 
GCSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and 
stem cells [Basu et al., 2002]. Further, GCSF stimulates the proliferation of mature 
neutrophils. 
GCSF was obtained at 4.2 mg/ml in 20 mM phosphate buffer at pH 4.0. For our 
studies the concentration was set to 0.5 mg/ml. 
2.1.1.3 rPA 
Reteplase (rPA) is a recombinant non-glycosilated form of human tissue plasminogen 
activator (alteplase), a thrombolytic drug [Nordt et al., 2003]. It was used as a further 
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model protein. rPA is formulated at 3.0 mg/ml in 500 mM arginine and 260 mM 
phosphate at pH 7.2. Concentration for experiments was set to 1.0 mg/ml. 
2.1.2 Chemicals and reagents 
Table 1: Chemicals and Reagents 
Reagent Description Supplier 
Glycine Ph.Eur. Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
L-Histidine Ph.Eur. Merck KGaA, Darmstadt, Germany 
D(+)-Sucrose Ph.Eur. VWR International, Darmstadt, 
Germany 
NaCl p.a. Merck KGaA, Darmstadt, Germany 
L-Arginine p.a. Applichem GmbH, Darmstadt, 
Germany 
NaH2PO4 * 2H2O p.a. Merck KGaA, Darmstadt, Germany 
Na2HPO4 * 2H2O min. 98% Merck KGaA, Darmstadt, Germany 
Polysorbate 80 Ph.Eur. Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
BSA Fraction V Merck KGaA, Darmstadt, Germany 
Sodium dodecyl sulphate (SDS) >99%, ACS Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Apura water standard Oven 1% 1% water Merck KGaA, Darmstadt, Germany 
KH2PO4  p.a. Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
K2HPO4 * 2H2O p.a. Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
KCl p.a. Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
2-Propanol for HPLC Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
Reversible Protein Detection Kit for membranes and 
polyacrylamide gels 
Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany 
NIST tracable size standard 150nm, 200nm, 
220nm, 240nm, 
269nm, 300nm, 
700nm 
Thermo Fisher Scientific (Pao Alto, 
CA, USA) 
Particle counting standard 300nm and 498nm Thermo Fisher Scientific (Pao Alto, 
CA, USA) 
Hydrazinsulfate Ph.Eur. Merck KGaA, Darmstadt, Germany 
Hexamethylentetramine Ph.Eur. Merck KGaA, Darmstadt, Germany 
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2.2 Methods  
2.2.1 Protein sample processing 
2.2.1.1 Shaking stress 
Mechanical shaking stress was performed with a Combidancer (Hettlab AG, Bäch, 
Switzerland) at 1000 rpm. Aliquots of 3.5 ml of each solution were filled into 4 ml 
Zinsser Analytic glass vials (Zinsser Analytic, Frankfurt, Germany) adequate for the 
Combidancer and sealed with screw caps with silicone seal disc (Zinsser Analytic, 
Frankfurt, Germany). Sampling of 3.5 ml glass vials (n = 3) was accomplished at 
defined time points: to assess the relevance of submicron particle counting 
(chapter 3), sampling from IgG1-α, GCSF and rPA formulations was performed every 
30 min and for IgG1-ß every 90 min. The determination of particulate matter of 
stressed protein solutions after dilution into serum solution (chapter 4) was performed 
after 2 h (rPA), 3 h (GCSF), 4 h (IgG1-α), and 9 h (IgG1-ß) shaking. Different shaking 
times were applied in order to generate sufficient concentration of particles. The 
dilution into different buffers (chapter 5) was performed after 5 hours shaking in order 
to study the effect of dilution, different pHs and standing time. 
2.2.1.2 Stirring stress 
For stress simulation experiments (chapter 7) stirring stress was performed in glass 
bottles at 150 rpm, 200 rpm, 300 rpm, 400 rpm, 500 rpm and 600 rpm using magnetic 
stirrer bars and magnetic stirrers with different dimensions (table 2). Glass containers 
were of different sizes and filling volumes: standard 5 ml glass type I vials filled with 
5 ml IgG1-α-formulation and crimped with crimping caps with silicone seal disc (West 
Pharmaceuticals, Eschweiler, Germany) during stirring, 100 ml glass bottles filled 
with 40 ml IgG1-α-solution and 500 ml glass bottles filled with 200 ml IgG1-solution 
(n=3). Furthermore, 2000 ml IgG1-α-solution were stirred at 400 rpm in a 5000 ml 
glass bottle (n=1). All used glass bottles and glass vials were from glass type I. The 
Duran® glass bottles (Duran Group GmbH, Mainz, Germany) were sealed with screw 
caps during stirring to prevent contamination with extraneous particles.  
 
 
 36 
Table 2: Dimensions of stir bars and glass bottles 
Dimensions     
Stir bar dimensions Short Side [mm] 
Long Side 
without Curve 
[mm] 
Long Side 
Total [mm] 
 
Stir bar 5 ml vial 3.00 6.00 4.00  
Stir bar 100 ml bottle 5.20 20.69 24.88  
Stir bar 500 ml bottle 7.47 33.73 39.90  
Stir bar 5000 ml 
bottle 9.89 74.47 81.70  
     
Bottle dimensions Total Height [mm] 
Height up to 
shoulder 
[mm] 
Outer 
Diameter 
[mm] 
Inner Diamter 
[mm] 
5 ml vial 40 25 20 18 
100 ml bottle 100 50 56 52 
500 ml bottle 176 97 86 82 
5000 ml bottle 330 199 182 176 
 
2.2.1.3 Thermal stress 
For thermal stress aliquots of 5 ml of each solution and corresponding placebo were 
filled into standard 5 ml glass type I vials (Schott, St. Gallen, Switzerland) and 
crimped using crimping caps with silicone sealing discs (West Pharmaceuticals, 
Eschweiler, Germany). The vials were placed at 65 °C (for both IgG1 formulations), 
60 °C for rPA and 50 °C for GCSF in a Heraeus hot-air cabinet (Haraeus, Hanau, 
Germany). Temperatures for thermal stresses were set to be at least 5 °C below the 
respective protein melting temperature Tm. Sampling (three vials of protein 
formulation and one vial of matching placebo were taken per sampling-point from the 
hot air cabinet) was accomplished at defined time points: to assess the relevance of 
submicron particle counting (chapter 3), sampling of both IgG1 formulations every 
20 min over 3 h, for GCSF and rPA formulations every 15 min over 2 h. To assess 
particulate matter in serum-solution (chapter 4), proteins were heated over 3 h at 
given temperatures. 
2.2.1.4 Freeze-thawing  
Freeze-thaw cycles were used in these studies to apply stress on therapeutic 
proteins. In order to determine the relevance of submicron particle counting 
(chapter 3) aliquots of 5 ml protein solution and corresponding placebo were filled 
into standard 5 ml glass type I vials (Schott, St. Gallen, Switzerland) and crimped 
using crimping caps with silicone sealing discs (West Pharmaceuticals, Eschweiler, 
Germany). At least five freeze-thaw cycles were performed using a -86 °C ULT 
 37
Freezer Thermo Scientific (Thermo Scientific, Karlsruhe, Germany). Sampling was 
performed after each cycle (3 vials with protein formulation and 1 vial with placebo 
formulation were sampled).  
To generate enough particles for particulate matter determinations after dilution into 
serum solution and buffers (chapter 4), ten freeze-thaw cycles were applied to rPA 
and GCSF. 
2.2.1.5 Lyophilization  
Lyophilization was performed using either a Christ Epsilon 2-12D freeze-dryer (Christ, 
Osterode am Harz, Germany) or a FTS Systems Durastop freeze-dryer (Stone Ridge, 
New York, USA). Aliquots of 3 ml were filled into TopLyo® vials (Schott, St. Gallen, 
Switzerland) and standard glass type I vials (Schott, St. Gallen, Switzerland) and 
partially stoppered with lyophilization stoppers (West pharmaceuticals, Eschweiler, 
Germany). 
A conventional freeze-drying cycle was applied (see table 3). During the lyophilization 
process product temperature was controlled using thermocouples. After freeze-drying 
the lyophilization chamber was vented with dry nitrogen up to a pressure of 1000 
mbar and the vials were completely stoppered.  
 
Table 3: Lyophilization parameters 
Step Ramp [K/min]  Shelf temperature [°C] Hold Time [min] Vacuum [mbar] 
Freezing 1.0 2 20 1000 
Freezing 0.8 -50 120 1000 
Primary Drying 0.5 -30 390 0,09 
 0.5 -35 3600 0,09 
 0.2 -20 600 0,09 
Secondary Drying 0.3 +20 600 0,013 
Venting and 
Unloading - +20 - 1000 
 
The freeze-dried samples were degassed after reconstitution with purified water 
using ultrasound bath Bandelin Sonorex TK 52 (SCHALLTEC GmbH, Mörfelden-
Walldorf, Germany) for 3 min to remove air bubbles. 
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2.2.2 Protein aggregate characterization methods 
In general, from each measuring point 3 vials with stressed protein and 1 vial placebo 
are taken. From each vial one measurement with each method is performed. The 
order of measurements in chapter 3 is always kept the same to have comparable 
results, starting with the most sensitive methods: particle counting with AccuSizer is 
performed directly after sampling, followed by light obscuration and Micro-Flow 
Imaging. Dynamic Light Scattering, Size-Exclusion Chromatography and turbidity 
measurements are performed subsequently. 
2.2.2.1 Particle counting  
2.2.2.1.1 Particle counting with AccuSizer FY nano (AS) 
Particles in the range from 150 nm to 10 µm were counted with an AccuSizer FY 
nano (PSS Nicomp, California). 1.5 ml sample was extracted from the vials via 
syringe and needle. For each sampling point 3 vials protein formulation and 1 vial 
placebo were sampled. The syringe was placed onto the AccuSizer port. After 10 min 
waiting to discharge micro and nanosized airbubbles the sample was injected into the 
instrument. In order not to stress the proteins and not to generate particles, the 
protein formulations were allowed to stand in the syringe for 10 minutes.  
Figure 1 shows a schematic representation of the optical system: Larger particles in 
the range from 0.61 µm are counted via light obscuration. In the range below 0.61 µm 
the light scattering detector comes into operation.  
 
 
Fig. 1: Two detectors system of AccuSizer 
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The AccuSizer FYCD Application software (Vers. 4.32) was set to collect data in the 
range from 0.61 µm to 10 µm over 90 seconds, in the range from 0.31 µm to 0.61 µm 
and in the range from 0.15 µm to 0.31 µm over 120 seconds. The system 
automatically conducts three measurements from the stirred, homogeneous sample. 
The first measurement is for the larger particles, the last measurement for the 
smallest particles. In parallel the automatic sample dilution takes place with a speed 
of 15 ml/min until the maximum of 2000 particles/second is counted in the respective 
measurement. During automatic sample dilution also a rinsing of the measurement 
system was accomplished. 
To better evaluate the results, the data were classified into different particle size 
classes, plotted cumulatively. The size classes ≥250 nm, ≥500 nm, ≥750 nm, ≥1 µm, 
≥2.5 µm, ≥5 µm and ≥7.5 µm were used. Originally, the particle size class >10 µm 
has also been chosen for evaluation, as its number is limited within pharmacopoeias. 
However, the AccuSizer was not able to detect any particles of this size class.  
2.2.2.1.2 Classical light obscuration (LO) particle counting 
Subvisible particles in the range from 1 - 200 µm were either counted with a light 
obscuration instrument Syringe (Klotz, Bad Liebenzell, Germany) using SW-CA2 
software and LDS23/25bs sensor or with a light obscuration instrument PAMAS 
SVSS-C (PAMAS, Bad Salzuflen, Germany), Sensor HCB-LD-25/25 (PAMAS, Bad 
Salzuflen, Germany). From each vial (n = 3 vials) one measurement of a volume of 
1.0 ml was performed, the instrument takes the defined volume automatically from 
the vials using a needle. The obtained results were averaged and standard 
deviations were calculated. The first measurement was always considered as rinsing 
and eliminated from calculations. 
To better evaluate the results, the data were classified into different particle size 
classes and plotted cumulatively. The size classes ≥1 µm and ≥10 µm were chosen. 
The pharmacopoeial requirements regarding subvisible particles are related to 
particles ≥10 µm and ≥25 µm, therefore the size class ≥10 µm is chosen.  
2.2.2.1.3 Microflow imaging (MFI) particle counting 
A second instrument to assess subvisible particles in the range from 1 - 100 µm is 
MFI (either DPA 4100 or DPA 4200, Brightwell Technologies, Toronto, Canada, now 
ProteinSimple, Santa Clara, CA, USA). From each vial (n = 3) one measurement of 
0.5 ml was performed. The samples were taken from the vials using an Eppendorf 
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pipette (Eppendorf AG, Hamburg, Germany) and barrier tips. The barrier tip prevents 
the samples to be contaminated with extraneous particles. The results were 
averaged and standard deviations were calculated.  
MFI DPA 4100 measurements and analysis was performed using DPA4100 software 
version 6.9.7.1. Measurements with DPA 4200 were carried out with MVSS software 
version 2, analysis was done with MVAS1.1. 
To better evaluate the results, the data were classified into different particle size 
classes and plotted cumulatively. The size classes ≥1 µm and ≥10 µm were chosen 
for comparison. 
2.2.2.1.4 Evaluation of particle counting measurements 
Observing strict rules is necessary when evaluating particle counting measurements. 
Otherwise comparison is impossible. We were interested to define the “point of 
detection”, where applied stress results in a significant increase of particle counts, by 
statistical analysis.  
At each sampling point one measurement is performed from three vials (n = 3), this 
also applies for the reference samples. From these three results the mean value and 
standard deviations (SD) are calculated.   
Mean values of particle counting measurements with their standard deviations were 
plotted over stress time to find the point where stress on the proteins results in 
aggregate formation, the “point of detection”. 
We defined the “point of detection” as the first measuring point with no overlap of its 
SD with the SD of the reference. Only for particle counting measurement this rule is 
extended due to generally high variability in counts. Especially after mechanical 
stress outliers are prevalent, increasing the mean of counted particles and the 
respective SD. An increased mean and SD would lead to a false “point of detection”. 
Therefore, also the averaged relative SD of all measuring points must not have an 
overlap at time point of detection. Observing both rules, a consistent evaluation of 
results was ensured.   
2.2.2.2 Microscopic examination 
Microscopic examination (chapter 5) was performed using Olympus BX50 
microscope (Olympus, Hamburg, Germany) and 10*0.30p U-PLan FI objective. The 
magnification used was 10-fold. 10 µm protein samples were placed on a microscope 
slide and pictures were taken. 
 41
2.2.2.3 Dynamic light scattering (DLS) 
Particle size distributions for IgG1-α and -ß (chapter 3) were measured with a 
Zetasizer Nano-ZS (Malvern Instruments, Germany) at 25 °C using ZetaSizer 
software (Vers. 6.01). The ZetaSizer Nano is performing non-invasive back-scattering 
technique (NIBS) with a 4 mW He-Ne-Laser at 633 nm. 
Each sample was recorded once with 20 subruns of 20 seconds. Z-average was 
evaluated, calculated from correlation function using ZetaSizer software.  
The hydrodynamic diameter of the native antibody was 11 nm. Denaturation of the 
monomer was assumed when the size of the main peak was ≥13 nm. The 
occurrence of additional large size peaks was interpreted as existence of protein 
aggregates.  
GCSF and rPA formulations were not assessed by DLS. 
2.2.2.4 Size-exclusion chromatography (SEC) 
Relative levels of remaining monomer and soluble aggregates were determined by 
SEC. 
An Agilent 1100 system (Agilent Technologies GmbH, Böblingen, Germany) was 
used for this study. UV-detection at 280 nm (IgG1-α, IgG1-ß, GCSF) and 215 nm 
(rPA) (table 3) was applied for quantification of relative amounts of monomer, 
dimer/trimer, fragments and soluble high-molecular weight (HMW) aggregates 
(chapter 3). Calculations were performed using ChemStation software 
(Vers. A.10.02). Relative amounts of insoluble aggregates were indirectly calculated: 
if recovery decreases, insoluble aggregates were assumed to form to the same 
amount.  
All samples (n = 3) were centrifuged at 14000 rpm over 10 min to separate from 
insoluble aggregates before injection. 
Areas under the curve were evaluated and the results of performed three 
measurements were averaged. The amount of monomer, dimer, fragments, oligomer 
and insoluble aggregates are calculated by percentage relatively to reference 
chromatogram and plotted in one graph. 
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Table 4: Size-Exclusion chromatography parameters 
Protein Column Pre-Column 
Injection 
volume 
[µl] 
Flow 
rate 
[ml/min]
Running buffer 
UV-
Detection 
[nm] 
Fluorescence-
Detection 
[nm] 
IgG1-α 
TSK-GEL 
G3000 SWXL 
7.8 mm ID * 
30.0 cm1 
TSK-
GEL 
SWXL1 
100 0.3 
0.25 M KCl, 0.2 
M potassium 
phosphate, pH 
7.0, 10% (V/V) 
isopropanol 
280 - 
IgG1-ß Superose 62 - 100 0.35 
0.01 M sodium 
phosphate, 0.5 
M NaCl, pH 7.0 
280 - 
GCSF 
TSK-GEL 
G3000 SWXL 
7.8 mm ID * 
30.0 cm1 
TSK-
GEL 
SWXL1 
100 0.6 0.1 M phosphate buffer, pH 7.0 215 - 
rPA 
TSK-GEL 
G3000 SW 7.5 
mm ID * 30.0 
cm1 
- 50 0.45  
0.5 M L-Arginin 
and H3PO4, pH 
7.2 
280 - 
any 
(Protein 
adsorption) 
TSK-GEL 
G3000 SWXL 
7.8 mm ID * 
30.0 cm1 
- 400 0.75 PBS; 0.05 mg/ml SDS - 
Intrinsic 
Fluorescence: 
Ext. 280 nm; 
Em. 334 nm 
1 Tosoh Bioscience GmbH, Stuttgart, Germany         
2 GE Healthcare, Freiburg, Germany     
 
Protein desorption of adsorbed protein was performed in chapter 6. The exact 
amount of desorbed protein (2.2.3.1) was determined via Size-Exclusion 
Chromatography (SEC) on an Agilent 1100 system and corresponding Agilent 1200 
fluorescence detector. Calculations were performed using ChemStation software 
(Vers. B.02.01). 6-point calibrations from 0.0001-0.01 mg/ml for each protein were 
performed to calculate the exact amount of desorbed protein. 
2.2.2.5 Optical density at 550 nm (OD) 
Measuring optical density at a high wavelength was used to determine turbidity with 
small sample volumes. 
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Optical density was determined at 550 nm using a Tecan GENios Plus Microplate 
reader (Tecan GmbH, Germany) using XFluor4 software. 200 µl sample were 
measured in a Nunc 96-well-plate.  
We were interested to find the “point of detection”, where applied stress resulted in a 
significant increase of turbidity. OD measurement results (n = 3) are averaged and 
standard deviations are calculated. The mean values are plotted over time with their 
relative standard deviations. The first point with no overlap of standard deviations 
mirrors the time “point of detection”. Additionally, OD values have to be ≥0.0287. 
Turbidity limits are defined by the pharmacopoeia, relationship to optical density was 
established (see chapter 3.3.6).  
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2.2.3 Other methods 
2.2.3.1 Quantification of protein adsorption to glass vials 
The adsorption behaviour of IgG1 on inner surfaces of standard 5 ml glass type I vials 
and 6R TopLyo® vials was studied adapting the standardized desorption method 
developed by Johannes Mathes [Mathes, 2010].  
Samples were prepared and split into different parts. One part of the samples was 
freeze-dried, reconstituted and degassed (n = 3 for both vials), one part of the 
samples was freeze-thawed (n = 3 for both vials), one part was kept as reference in 
the different vials (n = 3 for both vials) over 4 h to incubate the protein.  
To quantify the protein adsorption to glass vials via SDS-desorption, vials were 
quantitatively emptied after incubation of the protein solution. Into the empty vials 
respective formulation buffer was filled four times for 5 min and vials were 
quantitatively emptied after each cycle. Vials were centrifuged headfirst over 2 min at 
1500 rpm using a Megafuge 1.0R (Heraeus, Hanau, Germany). After the last cycle, 
0.05 % SDS in PBS (10 mM phosphate buffer and 145 mM NaCl) at pH 7.2 was filled 
into the vials and incubated for 24 h at 25 °C. 
2.2.3.2 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry was used to assess the physicochemical 
characteristics of the lyophilized cakes. A Netzsch DS Calorimeter 204 Phoenix 
(Netzsch, Selb, Germany) was applied to determine the glass transition temperature 
of the maximally freeze-concentrated solution (Tg’) and the lyophilizates (Tg). 
To determine Tg’ 20 µl were transferred into aluminium crucibles and cooled to -90 °C. 
Samples were then heated up to 10 °C to determine the glass transition. 
To determine Tg 5 - 10 mg of the dried lyophlizates were weighed into aluminium 
crucibles and sealed in a dry nitrogen atmosphere. Two heating scans were 
performed: cooling down to -20 °C and heating up to 100 °C, cooling down again to -
20 °C and heating up to 200 °C. Tg was determined from the heating scans. 
2.2.3.3 Karl-Fischer titration 
Residual moisture contents of the samples were determined using a Karl Fischer 
coulometric titrator Aqua 40.00 (Analytik Jena AG, Halle, Germany) with headspace 
oven. An oven connected to the reaction vessel and flushed with Nitrogen heated the 
lyophilized cake up to 80 °C. Dry nitrogen transported the evaporated water into the 
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titration solution and residual water was determined. Before and after measuring the 
sample batch, a pure water standard was analyzed, as well as at least three blank 
values. 
2.2.3.4 Zeta potential titration 
Zeta potential (ZP) and surface charge densities of proteins in solutions were 
measured using a ZetaSizer (Malvern Instruments, Herrenberg, Germany), operating 
with a 4 mW He-Ne laser at 633 nm. Measurements were performed in Malvern 
disposable zeta cells at 25 °C. A starting volume of 8 ml of filtered protein solution 
was filled into a polypropylene tube and stirred during measurement. The pH 
adjustment was computer-controlled by a MPT-2 Autotitrator (Malvern Instruments, 
Herrenberg, Germany); titration was performed using 0.1 M HCl to pH 4.0 (for IgG1) 
and 0.1 M NaOH to pH 12.0. Device control and final data analysis were performed 
using Malvern Dispersion Technology Software version 6.12 (Malvern Instruments, 
Herrenberg, Germany). 
2.2.3.5 Stress simulations 
Stress simulations were performed at 150 rpm, 200 rpm, 300 rpm, 400 rpm, 500 rpm, 
and 600 rpm using STAR-CCM+ software (CD Adapco, Nürnberg, Germany) in 5 ml 
standard glass type I vials, 100 ml, 500 ml, and 5000 ml Duran® glass bottles. 
To perform the complex calculations the following information was needed: viscosity 
and density of formulation, dimension of glass containers and magnetic stirrer bars 
and stirring speed. Exact bottle dimensions were obtained from Duran Group GmbH, 
Mainz, Germany. Exact stirrer bar dimensions were determined using a slide-rule. 
Stress tensor magnitudes [Pa] as the obtained stress unit were extracted from the 
simulations. 
Stress tensor magnitude is a parameter to quantify stress in Pascal, calculated by 
STAR-CCM+ software, using a complex three dimensional momentum Navier-Stokes 
equation, which describes the flow of Newton’s liquids: 
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Whereas t is the time, xi the Cartesian coordinate, ui the velocity component in 
direction xi, p the pressure, ρ the density, τij the stress tensor components and si the 
momentum source components.  
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Simplified, the Navier-Stokes equation describes: change of impulse + change of 
tensor over distance = change of pressure over distance. 
The Stress Tensor Magnitude is defined as ∑∑=
j
ij
i
T τ
2
1  
 
Fig. 2: Mesh refinement to capture the formulation surface and calculation into Stress Tensor Magnitude 
 
For the computational calculations a 3D-virtual mesh is built and the stress tensor is 
calculated for each cuboid. Mesh refinements are applied to exactly characterize 
areas where the IgG1-formulation has contact with glass, air or stir bar surfaces 
(figure 2). In those areas maximal (red) stress tensor is found, whereas minimal (dark 
blue) stress tensor is found in areas with no contact of IgG1-solution to glass, air or 
stir bar.  
For each cuboid stress tensors are calculated using STAR-CCM+ software. From 
those calculations the minimal and maximal averaged stress tensors are obvious. 
The averaged stress tensor is calculated by multiplying the stress tensor of each 
cuboid with the cuboids volume and dividing the result by the total volume of the 
cuboids.  
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3. Relevance of Submicron Particle Counting for 
Development and Quality Assurance of Protein 
Pharmaceuticals  
3.1 Introduction  
During the last years therapeutic proteins have become a major part of the modern 
drug portfolio and are the fastest growing group of new pharmaceuticals. Their 
specifity and efficacy opened new options in the treatment of severe diseases [Singh 
et al., 2010].  
Unfortunately, proteins are typically not very stable molecules, neither chemically nor 
physically. Denaturation, aggregation and precipitation can occur during manufacture, 
handling, storage and shipping and may compromise the pharmaceutical quality of 
protein drug products [Carpenter et al., 2008]. Stress factors inducing aggregation 
are elevated temperatures, exposure to light and interfaces [Bee et al., 2009; Bee et 
al., 2010], agitation [Eppler et al., 2010], freeze-thawing [Bhatnagar et al., 2007] or 
impurities [Chi et al., 2005; Jones et al., 2005; Thirumangalathu et al., 2009; Tyagi et 
al., 2008]. In extreme cases, loss of declared content and loss of efficacy can be a 
result of aggregation, but proper formulation and quality control will exclude such 
products from the patient. Difficulties arise, when small amounts of protein aggregate 
in otherwise stable formulations. The presence of aggregates and particles is not just 
a matter of “pharmaceutical quality” but compromises the safety of such products 
with regard to their immunogenicity [Barnard et al., 2010; Fradkin et al., 2009; 
Rosenberg, 2006; Schellekens, 2003; Schellekens, 2005]. 
It has become obvious that a certain correlation between presence of 
aggregates/particles and unwanted immunogenicity of protein drug products exists 
[Carpenter et al., 2008; Schellekens, 2003]. On the other hand it is still unclear, what 
type of aggregates, what sizes and numbers etc. may lead to clinically relevant 
immune reactions.  
In protein aggregates the native structure of the protein can either be retained or 
unfolded proteins can attach to each other. Furthermore, the aggregation can be 
irreversible or reversible [Mahler et al., 2008; Philo et al., 2009]. Aggregates can 
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cover the size range from a few nm (as for protein dimers) up to large precipitates, 
visible with the unaided eye (i.e. more than about 80 µm in size).  
Before any further conclusions can be drawn and measures can be taken about the 
safety of aggregates and precipitates in protein drug products, the size and numbers 
of such aggregates have to be measured with reliable methods. 
One single method covering the whole range of aggregate sizes and types does not 
exist [Das et al., 2008; Narhi et al., 2009]. Therefore, complementary methods must 
be used and existing methods have to be improved or better methods have to be 
developed.  
In general, particulate matter has to be measured in parenteral drug products as set 
out in the pharmacopoeias [European Directorate For The Quality of Medicine 
(EDQM), 2011b; United States Pharmacopeia, 2009]. The USP and EP both have set 
limits for subvisible particles ≥10 µm and ≥25 µm to be counted by light obscuration 
(LO) or by microscopic methods and in addition ask for the absence of visible 
particles in parenterals. Originally these limits had been set for “extraneous, mobile 
and undissolved impurities” of any origin, including those from filters, packaging 
material, machinery, airborne dust etc. With protein solutions emerging on the market, 
these specifications have been kept and the same limits for particle sizes and 
numbers still apply, but the origin of particles has in many cases dramatically shifted 
towards aggregated and precipitated protein drug. With that background in mind it 
must be questioned, whether the existing specifications are still appropriate and 
meaningful, and if not, how they may be adapted to the actual situation. Subvisible 
particles <10 µm are not considered at all in the actual pharmacopoeial specifications. 
Of course, smaller particles are often present in protein solutions, their numbers need 
to be determined and their relevance must then be discussed [Golub et al., 2007; 
Mahler et al., 2005]. 
Although we have a large number of particle sizing and counting methods, including 
light blockage (LO), coulter counter (CC), micro flow imaging (MFI), dynamic light 
scattering (DLS) etc. we do not routinely use them from 1-10 µm and we have 
difficulties to reliably count particles below 1 µm , e.g. in the range from 100-1000 nm. 
Many methods, preferably DLS, detect and size such particles but cannot count, i.e. 
determine the number per volume [Malvern, 2007].  
Classical light obscuration instruments and MFI systems have their lower detection 
limit at about 1 µm. On the other hand, it is possible to determine aggregates <1 µm 
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semiquantitatively by dynamic light scattering and chromatographic methods. The 
chances and limitations of SEC have been reviewed extensively elsewhere [Barnard 
et al., 2010]. SEC measurements might lead to false negative results due to 
adsorption of protein to the column matrix, reversibility of aggregates, and inability of 
large aggregates to the pass column frit and underestimation of aggregate species 
with UV-detection [Carpenter et al., 2009; Philo, 2009]. Dynamic light scattering 
(DLS) on the other hand allows detection of aggregates sized between 10 nm and 
1000 nm but due to the bulk nature of the measurement, the presence of a few large 
aggregates can dominate the entire size distribution and lead to artefacts [Demeester 
et al., 2005].  
Hence, reproducible quantification, i.e. counting of particles in the submicron range of 
0.1-1 µm is practically not possible [Carpenter et al., 2008].  
At that point it is our intention to provide new insight into the performance of existing 
and new methods and to come to new recommendations how to proceed. 
This study highlights the data generated with a new instrument promising to partly 
close the existing size gap below 1 µm and to provide particle counting from the 
lower µm range down to about 200 nm. A new two-detector-system, the AccuSizer 
FY nano® (PSS Nicomp, CA, USA), is marketed with nominal detection and counting 
limits of 0.15-10 µm [Nicomp, 2008]. 
The instrument itself dilutes the samples until an eligible count of particles is 
achieved, whereby coincidences of particles shall be avoided. A caveat is that protein 
aggregates that are reversible with dilution could be generally underestimated 
[Demeule et al., 2010]. The AccuSizer employs two detector systems: a light 
obscuration detector is counting particles from 610 nm to 10 µm. The second 
detector is a light scattering detector counting particles from 150 nm to 610 nm by 
sensing different intensities of scattered light which are related to defined sizes.  
AccuSizer uses focused extinction for evaluation of results: only a few particles 
flowing through the focus located in a small fraction of the flow cell are counted. 
Those particle counts are recalculated to give the overall particle counts for the entire 
flow cell and finally the particle counts per ml of sample solution.  
We rigorously assessed the AccuSizer in comparison to classical instruments: Four 
model proteins were stressed thermally, mechanically and by freeze-thawing. At 
defined time points samples were collected and analytics were performed. Particle 
count, monomer loss and turbidity were determined over time. Results of AccuSizer 
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(AS) were compared to the classical methods: Light obscuration (LO), Size-Exclusion 
Chromatography (SEC), Dynamic Light Scattering (DLS), turbidity or Optical density 
at 550 nm (OD).  
Electrical sensing zone instruments (coulter counter, CC) also claim to have a 
detection limit below 1 µm, e.g. at about 400 nm. Our group has studied the 
performance of the CC technique versus LO before [Mück, 2002] and found a 
“usable” lower detection limit of about 700 nm, not 400 nm, due to high background 
signals at the smaller size channels from 400 nm to about 700 nm. It has been the 
conclusion in our previous studies that CC will not deliver more relevant information 
on particle formation compared to LO. In the previous study we successfully 
employed a novel concept to assess the performance of the particle counting method, 
that did not directly compare the absolute numbers of particles counted but the onset 
of particle formation when formulations were stressed over time: The ability of a 
counting method to reliably detect and quantify whether a formulation aggregates 
and forms particles after a certain amount of applied stress or not appears most 
important to us. This concept implies also the expectation that a method counting 
smaller particles might allow the earlier and more sensitive detection of aggregation. 
Counting smaller particles may allow to find “precursor” particles at an earlier time 
point compared to methods starting at >10 µm. 
In summary, the aim of the study is first to decide whether a new method is really 
able to reliably count protein aggregates sized below 1 µm and secondly if data on 
particle counts below 10 µm or even below 1 µm would provide more useful 
information to the formulations scientist than the existing, traditional counting >10 µm. 
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3.2 Experimental setup 
The protein formulations were filtered using a 0.1 µm Millex syringe-driven filter unit 
(Millipore, Carrigtwohill, Ireland) into a particle free beaker and filled into particle free 
vials. For each sampling point three vials with protein formulation and one vial with 
placebo were prepared. From each vial all used analytical methods were performed.  
Four different proteins were stressed over time using three different stresses: 
Thermal and mechanical stress and freeze-thawing. During stress samples were 
taken and analytics were performed with five different methods: classical light 
obscuration (LO) at particle size channels ≥10 µm as required by USP and Ph.Eur. 
and at channel ≥1 µm in addition, Microflow imaging (MFI) at particle size channels 
≥1 µm and ≥10 µm, dynamic light scattering (DLS), size-exclusion chromatography 
(SEC), optical density evaluation at 550 nm (OD) and AccuSizer (AS) measurements 
at particle size channels ≥250 nm, ≥500 nm, ≥750 nm, ≥1 µm, ≥2.5 µm, ≥5 µm and 
≥7.5 µm. To avoid redissolution of aggregates standing times were kept as short as 
possible. Immediately after stressing all samples were measured with particle 
counters, starting with more sensitive AS. Maintaining this order made sure that 
comparability between measurements in case of redissolution was still given. 
Results were evaluated and compared. We had a specific interest to assess the 
methods by their ability to detect changes in the formulation quality, i.e. the formation 
of larger aggregates and particles, at an early timepoint. Therefore we introduced the 
concept to determine “a point of detection” at which the applied stress resulted in 
formation of aggregates or particles or in loss of monomer content. The concept is 
visualized in figure 1. 
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Fig. 1: Experimental setup 
 
All in all we assessed for each Protein/stress combination (12 combinations) data at 
6 or more time points and 6 methods. The results of the three particle counters were 
subdivided and different particle size classes were assessed: for LO and MFI particle 
size classes for particle ≥1 µm and ≥10 µm, for AS particle size classes for particles 
≥250 nm, ≥500 nm, ≥750 nm, ≥1 µm, ≥2.5 µm, ≥5.0 µm and ≥7.5 µm (in total 11 data 
sets from particle counters for each time point). This huge amount of data sets (at 
least 84 for one single experiment; 12 experiments in total) can not completely be 
presented in this article. Therefore we evaluated raw data according to find the “point 
of detection”. The pre-evaluated data for all 12 experiments can be found in appendix 
(chapter 9).  
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3.3 Results and discussion 
3.3.1 Light obscuration measurements with USP-qualified LO instruments in 
comparison to AS 
The first study should elucidate how light obscuration measurements from traditional 
LO systems are compared to the new AccuSizer FY (AS) system. 
First, we decided to use particle sizes of ≥1 µm to compare the systems. Both 
systems are technically very well able to count particles of this size class and we 
want to include as much particles of small size into the comparison as possible. 
Besides, though the upper detection limit of AS was declared by the manufacturer to 
be 10 µm any particles ≥7.5 µm were detected.  
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Fig. 2: Light obscuration measurements with LO instrument (light gray) and AccuSizer FY nano (dark 
grey) of freeze-thawed IgG1-α; particles ≥1 µm; n = 3 
 
 
Particle counts for particles ≥1 µm were taken after stresses were applied and plotted 
over stress. As the AccuSizer FY uses focused extinction and autodilution as special 
tools absolute counts of particles cannot be compared (figure 2). It is noticeable that 
AS detects up to 10-fold more particles in this size class than LO does. But 
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evaluation of the results clearly revealed that both instruments have the same trend 
of detecting the onset of particle formation. The Klotz instrument (LO) and the 
AccuSizer (AS) judged beginning aggregation in most of the cases at exactly the 
same time (table 1). Only in 2-3 cases of 12 protein/stress combinations the ability to 
determine the “point of detection” of LO and AS differed. 
 
Table 1: Point of detection determined with LO and AS for particles ≥1 µm, more data in appendix 
 LO* AccuSizer* 
IgG1-α thermal 7 8 
IgG1-α mechanical 4 1 
IgG1-α freeze-thaw 2 2 
IgG1-ß thermal 4 4 
IgG1-ß mechanical 1 1 
IgG1-ß freeze-thaw 2 2 
GCSF thermal 1 1 
GCSF mechanical 2 1 
GCSF freeze-thaw 2 2 
Reteplase thermal 6 5 
Reteplase mechanical 1 3 
Reteplase freeze-thaw 2 1 
* numbers express the point of detection 
 
Interestingly a strong difference is seen in cases where mechanical stress had been 
applied. Two explanations are obvious. First, the standard deviation of the particle 
counts is compared to other samples very high for particle formation after mechanical 
stress. Second, autodilution and focused extinction by the AS system potentially 
leads to artefacts when measuring particles with a tendency for redissolution. 
Particles formed after mechanical stress show such a tendency [Kiese et al., 2010] 
and are therefore prone to being counted with high statistical error. In our studies 
high standard deviations can lead to a virtually later “time point of detection” (see 
2.2.2.1.4).  
Overall, the results after measuring four different proteins provide evidence that both 
LO instruments provide the same information when onset of particle formation is to 
be detected with the exception of samples after short term heavy mechanical stress. 
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3.3.2 Focused extinction and autodilution of AS 
Although AS had a nominal counting limit of 10 µm it did not show any particle count 
for particles >7.5 µm. This might be explained by the focused extinction of AS. 
Focused extinction means that measurements are not performed counting all 
particles within the flow channel. Only a small spot of the channel is statistically 
evaluated and might lead to imprecise results in case the particle count is low. 
However, even in samples in which light obscuration is counting hundreds of particles 
>10 µm AS is not counting one single particle ≥7.5 µm (data not shown). Therefore, 
this rationale can not be adhered.  
Autodilution can be considered as a disturbing factor for measurements of protein 
aggregates. There is the possibility that the measured aggregates within the samples 
are reversible by dilution and therefore not existent anymore during measurements. 
To evaluate this, measurements of stressed protein samples were performed with 
and without autodilution. Comparison showed that runs with autodilution did not 
result in different numbers for those measurements without autodilution. Curves of 
particle increase showed the same trend with small deviations to both sides (data not 
shown). From these results, autodilution can be excluded as a factor that resolves 
protein particles. 
3.3.3 Is the very early onset of aggregation detectable with AS? 
3.3.3.1 Lower detection limit of AS 
AS is claimed to have a lower detection and counting limit of 150 nm. No other 
particle counting system for pharmaceutical use provides this opportunity at the 
moment. In a first step particle sizing standards were measured to confirm the correct 
setup of the device.  
Figure 3 illustrates, that the instrument has the ability to detect particles in the 
nanometer range. AS can distinguish between particle sizing standards of 200 nm, 
220 nm, 240 nm, 269 nm and 300 nm. The existence of a peak at 330 nm points to 
the presence of air bubbles, which was proven in former experiments (data not 
shown). Also particle sizing standards of 700 nm are detected. The lowest particle 
size detected is 160 nm, the particles used are declared as 150 nm. These results 
show that the lower detection limit has to be shifted slightly towards larger particle 
sizes but in general the system is able to work reliably at least at 200 nm and for 
larger particles. 
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Fig. 3: Measurement of particle sizing standards: 150 nm, 200 nm, 220 nm, 240 nm, 269 nm, 300 nm and 
700 nm 
 
Furthermore the lower counting limit of AS had to be confirmed. For this purpose 
particle counting standards 300±6 nm and 498±5 nm were measured. The given 
concentration of particles in corresponding particle sizes are 1*109 particles/ml. 
For the standard 300 nm 1.13*109 particles/ml ± 4.50*107 particles/ml were counted; 
for the standard 498 nm 7.4*108 particles/ml ± 1.82*107 particles/ml were counted. 
This result shows that the AS is very well able to count particle in very low size 
ranges, at least from 300 nm upwards. 
3.3.3.2 Onset of aggregation and particle formation 
Further it should be assessed whether it is possible to get more information about the 
onset of aggregation by measuring extremely small particles in the upper nm range, 
i.e. below the 1 µm limit of traditional light obscuration counting with AS. In theory, 
small aggregates are considered as precursors or nuclei for aggregation [Golub et al., 
2007; Mahler et al., 2005]. Hence, small particles should be earlier detectable than 
larger ones.  
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Fig. 4: Light obscuration measurements with Klotz instrument (LO particles ≥1 µm; grey) as well as light 
scattering measurement with AccuSizer (AS particles ≥750 nm, dark grey; AS particles ≥250 nm, light 
grey) of heated reteplase; n = 3; sampling every 15 minutes 
 
However, despite the given ability of the AccuSizer FY to detect and count particles 
in the nanometer range, our experiments could not reveal reliable information about 
the early onset of aggregation. Only one out of 12 experiments resulted in an early 
increase of particle counts (“point of detection”) in the size class ≥0.25 µm (see 
appendix), whereas size classes ≥0.75 µm and ≥1.0 µm provided more information. 
Theoretically, small particles are expected to be earlier detectable than larger 
particles. High background noise makes it statistically almost impossible to detect 
small amounts of small aggregates.  
rPA that is susceptible to heat stress was chosen as an example: Figure 4 shows a 
particle count increase for particles ≥1 µm measured with LO after 75 minutes, for 
particles ≥0.75 µm measured with AS after 45 minutes, whereas particles ≥0.25 µm 
measured with AS could not clearly show beginning aggregation due to the high 
background noise in the smaller particle size range. 
The high background noise (figure 4) during measurements leads us to propose not 
to set value on the particle size channels close to the lower detection limit of AS. Only 
detection of particles ≥0.75 µm was found out to be meaningful. AccuSizer uses two 
detectors to count particles. The light obscuration detector is employed from 0.61 µm 
up to 10 µm and evidently works well. The light scattering detector (0.15 µm to 
0.61 µm) is able to size but not to properly count protein aggregate particles. This 
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might be traced back to the fact that light scattering is not the best way to quantify 
particles of a wide size distribution as the AS software uses the amount of scattered 
light and the particle sizes to calculate particle numbers.   
A comparable overall situation could be shown before with similar experiments with 
an electrical sensing zone instrument (CC) [Mück, 2002]. Proteins were stressed and 
samples were measured with classical LO instrument and Coulter Counter (CC). It 
was shown that the claimed lower detection limit of the CC did not give any additional 
information and had to be corrected from 0.4 µm to 0.7 µm.  
For the time being we conclude that these measuring systems that are theoretically 
able to count particles in the upper nanometer range do not provide benefit over 
classic LO detection when particle formation in the course of protein aggregation is to 
be evaluated. 
Further steps in the direction to count particles as an indicator for beginning protein 
aggregation would only be possible, if the background noise could be strongly 
reduced. 
3.3.4 Aggregation theory 
In theory, protein aggregation starts with building of small aggregates that 
accumulate to larger ones [Mahler et al., 2005].  
Due to this theory aggregation after stressing proteins over time should first be 
detectable with particle size classes of ≥250 nm, then of LO ≥1 µm, later with 
particles size classes ≥10 µm. However, as elaborated in chapter 3.3.3 high 
background noise interferes with particle counts in the nanometer range. Therefore, 
interesting information about the onset of aggregation in the range <750 nm could not 
be provided. 
When particle counts detected with classical LO instrument are compared, it turned 
out that particle counts in the size class ≥1 µm (figure 5) increases slightly earlier 
than in the size class ≥10 µm after e.g. freeze-thawing GCSF.  
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Fig. 5: Light obscuration measurements of freeze-thawed GCSF; particles ≥1 µm (dark grey) and ≥10 µm 
(light grey); n = 3 
 
12 experiments were performed: four different proteins were stressed by freeze-
thawing, heating and mechanically. An earlier increase of particle counts of particles 
>1 µm than for particles >10 µm was observable for six experiments (see bold prints 
in table 2). However, between detecting particles >1 µm and >10 µm only marginal 
delays are noticeable – four out of 12 experiments led to same time point of 
aggregation detection in both size classes, whereas in two out of 12 experiments 
even an earlier increase of the larger aggregates was detected.  
But experiments with rPA and GCSF, which are supposed to be less stable, 
compared to antibodies, give evidence for the earlier formation of smaller particles 
than of larger ones. The more stable antibodies mainly show the same point of 
detection for particle formation.  
For the time being, benefit of detecting particles >1 µm instead of particles >10 µm 
seems to be small, as it is not informative for all proteins. Detection of particle 
formation in antibody formulations, which are nowadays very important products and 
projects in pharmaceutical industry, does not deliver the wanted information. 
However, as LO measurements automatically delivers the additional information 
about particle formation of particles in the size class >1 µm, it would not be much 
more time effort to assess the available data.  
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Table 2: Point of detection determined with LO for particles ≥1 µm and ≥10 µm 
 LO 1 µm* LO 10 µm* 
IgG1-α thermal 7 7 
IgG1-α mechanical 4 1 
IgG1-α freeze-thaw 2 2 
IgG1-ß thermal 4 4 
IgG1-ß mechanical 1 1 
IgG1-ß freeze-thaw 2 3 
GCSF thermal 1 4 
GCSF mechanical 2 1 
GCSF freeze-thaw 2 3 
Reteplase thermal 6 -**
Reteplase mechanical 1 2 
Reteplase freeze-thaw 2 3 
* numbers express the point of detection 
** no detection of particles ≥10 µm during experiment, point of detection > 8
 
However, in another experiment IgG1-α was freeze-thawed over five cycles to 
generate particles. Thereafter, solutions were stirred at different speeds. Figure 6 
gives a hint, that large particles formed by freeze-thawing are crushed by stirring into 
smaller ones. Monitoring only particles ≥10 µm and ≥25 µm as required by the 
guidelines would disregard those small particles.  
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Fig. 6: Particle count of particles ≥1 µm (dark grey) and ≥10 µm (light grey) after stirring of freeze-
thawed IgG1-α; n = 3 
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3.3.5 Comparison of AS with DLS 
As shown in chapter 3.3.3 it had not been possible to detect particles in nanometer 
size range with AS due to high background noise. Theoretically it could be possible, 
that there were no particles in the sizes <750 nm. This was checked by DLS 
measurements. Though DLS does not provide absolute particle counts, it is able to 
detect particles <750 nm, although the intensity of the DLS signal for larger particles 
is dominant compared to smaller ones [Demeester et al., 2005; Malvern, 2007].  
To evaluate DLS data with regards to the “point of detection”, Z-averages of the 
measured particle diameters [nm] were plotted over time. Using DLS, different 
changes in protein samples can be detected: shift of the monomer peak towards 
larger sizes and formation of an additional peak. In general we found that heat 
stressed antibody samples provide a monomer peak shift to larger sizes, whereas 
mechanically stressed or freeze-thawed antibody solutions present an additional 
peak caused by large particles. 
DLS measurements of heat stressed IgG1-α resulted in a peak shift and increase of 
Z-average after 20 minutes. This peak shift was still in the size range of an IgG1 
monomer, therefore theoretically not detectable with the AS. After 120 minutes 
heating at 65°C the peak shifted to higher sizes around 200 nm (figure 7), after 
140 minutes an additional second peak (~1000 nm) was formed (figure 8). Both 
changes theoretically should have been detected by AS. Though, detection of 
particles >250 nm was only possible after 160 minutes (figure 9). 
 
 
Fig. 7: DLS measurements after 120 minutes heat stress at 65°C IgG1-α; peak shifted to ~200 nm 
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Fig. 8: DLS measurements after 140 minutes heat stress at 65°C IgG1-α; peak shift and additional peak 
 
 reference 20min 40min 60min 80min 100min 120min 140min 160min
SEC          
DLS          
OD550          
LO ≥1.0 µm          
LO ≥10 µm          
AS ≥1.0 µm          
AS ≥0.25 µm          
AS ≥0.75 µm          
AS ≥0.50 µm          
AS ≥2.5 µm          
AS ≥5.0 µm          
AS ≥7.5 µm          
Fig. 9: Heat stress of IgG1-α; detection power of different methods (results of particle counters were 
distinguished in different size classes, n = 3) 
 
In another experiment, the effect of freeze-thaw stress on IgG1-α was detected in 
larger particle size classes of both used particle counters after the 2nd cycle (figure 
10), DLS measurements detected large particles only after the 3rd cycle (figure 11, 
see arrow). An increase of aggregates in the particle size class of particles ≥250 nm 
was not detected at all by AS. Similar observations could be made after mechanical 
stress (data not shown): Particle counters detected aggregates ≥0.75 µm resp. 
≥1 µm before DLS instrument did, nanosized aggregates were not detected at all. 
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 reference 1.cycle 2.cycle 3.cycle 4.cycle 5.cycle 
LO ≥10 µm       
LO ≥1.0 µm       
AS ≥1.0 µm       
AS ≥2.5 µm       
AS ≥0.50 µm       
AS ≥0.75 µm       
DLS       
OD 550       
SEC       
AS ≥5.0 µm       
AS ≥7.5 µm       
AS ≥0.25 µm       
Fig. 10: Freeze-thawing of IgG1-α; detection power of different methods (results of particle counters were 
distinguished in different size classes; n = 3) 
 
 
Fig. 11: DLS measurements after 3rd cycle freeze-thawing of IgG1-α; generation of aggregates led to an 
additional peak; n = 3 
 
All in all, DLS measurements showed a peak shift after heat stress of antibodies. The 
shifted peak theoretically should have been detected earlier by AS, as even the LO 
system revealed in its measurements for particles ≥1 µm and ≥10 µm an increased 
particle count. 
A different situation is given after freeze-thawing and shaking of antibodies. LO and 
AS instruments were able to show increases of particle counts in µm ranges, though 
DLS measurements did not reveal a second peak. Anyhow, no changes in solution 
were detected by AS in the nanometer range.  
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Summarizing, DLS measurements after heat stress demonstrated that particles in 
nanometer range are existent.  
3.3.6 Comparison of AS with turbidity measurements 
Monitoring liquids for clarity/turbidity is also required by the pharmacopoeia (e.g. 
Ph.Eur.6.0, 2.2.1). Measuring turbidity is a very fast method, instruments are not 
expensive and easy to handle. Increasing turbidity is accompanied with an increasing 
amount of scattered light detected by a light detector is employed in a 90° angle. 
Particle or aggregate formation can lead to light deflection, which also diminishes the 
detected light. Therefore, turbidity measurements are taken into account for our 
studies and compared with detection abilities of AS.  
Nephelometry is the method of choice; however needed sample volume is often too 
large as research and development have restricted sample availability. Therefore 
relationship between nephelometry and measurement of optical density (OD) at 
550 nm is established. Measuring OD takes up only 100 µl sample volume. 
Turbidity standards [European Directorate For The Quality of Medicine (EDQM), 
2011a] were prepared and measured with both methods to obtain following 
relationship:  
OD = 0.0007 * FNU (nephelometry) + 0.0266 (with R2 = 0.9906; data not shown).  
By definition turbid liquids have a FNU-value ≥3 FNU; therefore OD ≥0.0287 is the 
corresponding limit. 
Turbidity theoretically directly correlates with generation of aggregates [Eckhardt et 
al., 1994]. Formed particles scatter incident light of an appropriate wavelength, thus 
turbidity increases with increasing particle count within the solution. However, a 
certain degree of OD or turbidity cannot be related to a certain particle size.  
The onset of turbidity was measured for all 12 experiments: 4 different proteins and 3 
different stress methods (data in appendix, chapter 9).  
In our example a significant increase of OD after 80 minutes and a further steep 
increase of OD after 140 minutes can be found (figure 12). However, particles 
≥250 nm were detected only after 160 minutes by AS (figure 9). 
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Fig. 12: OD measurements after 120 minutes heat stress at 65°C IgG1-α; steep increase of OD after 
140 minutes; n = 3 
 
Table 3: Results from turbidity measurements  
 Turbidity* 
IgG1-α thermal 4 
IgG1-α mechanical 1 
IgG1-α freeze-thaw -** 
IgG1-ß thermal 2 
IgG1-ß mechanical -** 
IgG1-ß freeze-thaw -** 
GCSF thermal -** 
GCSF mechanical -** 
GCSF freeze-thaw -** 
Reteplase thermal 6 
Reteplase mechanical 2 
Reteplase freeze-thaw 1 
* numbers express the point of detection 
** no detection of turbidity during experiment 
 
Monitoring optical density is not as significant as e.g. counting particles: only six out 
of the 12 stress experiments causes an increase in optical density (table 3). Six 
stress experiments did not result in an increase of optical density. 
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Turbidity turned out to be a good indicator for thermally stressed antibodies – in these 
cases observing was reliable as turbidity increases reliably early. However, stressing 
antibodies by freeze-thawing did not lead to an increase of turbidity, whereas 
mechanical stress did only result in turbid samples of IgG1-β. GCSF samples did not 
show turbidity after any stress, whereas rPA samples got turbid even after freeze-
thawing. 
Optical density measurement is an economical inspection method. Monitoring optical 
density/turbidity is fast and low priced, but provides no constant information about 
aggregation of proteins. Hence, it should not be the only method to depend on. 
3.3.7 Comparison of AS with SEC 
SEC is a common method to monitor protein aggregation. Though SEC is not able to 
give aggregate counts, it is a good method to give information about the relative 
amount of protein aggregation and protein monomer. In general, SEC turned out to 
be the best tested method to detect changes due to heat stress [Philo, 2009], see 
appendix. Heating proteins means supplying energy to the samples, this leads to the 
formation of small aggregates [Hawe et al., 2009].  
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Fig. 13: SE-HPLC of 65°C stressed IgG1-α; n = 3 
 
Generation of soluble high molecular weight (HMW) aggregates and dimers/trimers 
started after 20 minutes heating IgG1-α at 65°C (figure 13). Dimers and trimers could 
not have been detected by AS. Monomer (11 nm diameter) is decreasing over time, 
whereas aggregates are increasing. Insoluble aggregates are indirectly detected by 
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recovery rate after 140 minutes, which is fully congruent with LO data (figure 13 and 
figure 9). At least these large insoluble aggregates should also have been detected 
by the size class for particles ≥250 nm of AS, however particles were only detected 
after 160 min (figure 9). 
SEC also turned out to be a good method to detect changes in GCSF- and rPA 
samples after mechanical and freeze-thaw stress. GCSF and rPA are more 
susceptible to stress than monoclonal antibodies are, therefore mechanical and 
freeze-thaw stress both led to the formation of higher amount of insoluble particles, 
visible as decreasing recovery rate (figure 14). 
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Fig. 14: SE-HPLC of freeze-thawed GCSF; n = 3 
 
Shaking and freeze-thawing of monoclonal antibodies also assemble insoluble 
particles. Though, the absolute loss of protein was not high enough to become 
noticeable by SEC [Hawe et al., 2009]. Figure 15 shows an example: Freeze-thawing 
IgG1-α does not result in an amount of insoluble protein particles high enough to be 
detectable by SEC. The absolute loss is calculated as recovery rate and related to 
protein monomer.  
 70 
95%
96%
97%
98%
99%
100%
reference cycle 1 cycle 2 cycle 3 cycle 4 cycle 5
Time [minutes]
Insoluble
aggregate %
Soluble HMW
aggregate %
Dimer/trimer%
Fragment %
Monomer %
 
Fig. 15: Freeze-thawed IgG1-α; n = 3 
 
Concluding, all methods assessed are qualified to monitor changes in protein 
solutions. Reckoning the results of all measurements, an almost overall image is 
received. Though, one single method has a limited range of detection due to size 
limits, background noise, sensitivity or other interference factors. Further, the 
measurements provide different resulting parameters: count and size of aggregates, 
existence of changes, relative amount and size of aggregates. For the time being, 
evaluating results from one single method is not sufficient to get an overview about 
the aggregates in solution.   
3.3.8 Does MFI deliver early information? 
It is reported in literature, that MFI delivers more information regarding particle 
formation within protein formulation due to its higher sensitivity regarding translucent 
particles [Huang et al., 2008; Sharma et al., 2010].  
Table 4 shows the results of MFI particle counting compared to classical LO particle 
counting, whereas the numbers indicate the quantity of first detection as a 
comparison of LO and MFI. The quantity of “point of detection” expresses the number 
of experiments with an earlier detection of particle formation than the respective other 
instrument. For example, a “2” for LO means that LO was in two experiments able to 
detect increasing particle formation earlier than MFI. It is already reported in literature 
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[Hawe et al., 2009] and also carved out in these experiments that particle counters 
are not dedicated to detect changes in protein formulations after thermal stress. Even 
MFI is not sensitive enough to detect those changes. From table 4 it can be 
concluded, that MFI is the best method to detect particle formation after freeze-thaw 
stress, whilst LO proved to be better at detecting particles formed during mechanical 
stress.  
 
Table 4: Detection abilities of MFI compared to LO for particles ≥1 µm and ≥10 µm (the bigger the 
number the more sensitive the instrument) 
  Particles ≥1 µm Particles ≥10 µm 
  LO MFI LO  MFI 
Freeze-thawing 2 3 1 3 
Mechanical stress 3 2 3 1 
Thermal stress 2 2 1 2 
 
To further evaluate and explain these results, absolute particle counts and particle 
pictures of mechanical and freeze-thaw stress were checked for each protein. Due to 
above mentioned reasons we focused on particle formation after freeze-thawing and 
mechanical stress. 
In chapter 2.2.2.1.4 it is explained how the “point of detection” after particle counting 
is evaluated. For these further evaluations we decided only to consider data points 
with standard deviations (SD). Due to high standard deviations after mechanical 
stress, a different picture about methods’ sensitivity can be drawn (table 5): again 
MFI is the most sensitive method to detect particle formation after freeze-thaw stress. 
After mechanical stress, both instruments seem to be equal regarding their detection 
sensitivity. Going more into detail, MFI is very sensitive in detection of GCSF-, rPA, 
and IgG1-α-particles formed after both mechanical and freeze-thaw stress, whereas 
LO is more sensitive for particle detection of IgG1-ß-particles.  
 
Table 5: Detection abilities of MFI compared to LO for particles ≥1 µm and ≥10 µm without regard to 
averaged standard deviations  
  Particles ≥1 µm Particles ≥10 µm 
  LO MFI LO  MFI 
Freeze-thawing 2 3 1 3 
Mechanical stress 3 3 4 4 
 
Further we scrutinized the pictures of protein particles taken by MFI. It became 
obvious, that protein particles formed after mechanical stress and freeze-thawing of 
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GCSF, rPA, and IgG1-α are a mixture of both translucent and dark particles (example 
in figure 16). 
 
 
Fig. 16: Examples of GCSF particle pictures after mechanical stress  
 
In contrast, IgG1-ß particles after freeze-thawing and mechanical stress are 
consistently dark (example in figure 17). 
 
  
Fig. 17: Examples of IgG1-ß particle pictures after mechanical stress 
 
To study the different effect of mechanical and freeze-thaw stress on IgG1-ß, both 
IgG1 formulations were compared with regards to their excipients. Both IgG1 are 
formulated in histidine buffer and sugars. IgG1-ß is stabilized with polysorbate 80 
(PS-80), which obviously influences the appearance of protein particles.  
Polysorbates are reported to protect protein formulations against the formation of 
protein aggregates although they bind negligible to immunoglobulins [Garidel et al., 
2009]. Further it was found that PS can form peroxides [Ha et al., 2002] and fatty 
acids [Kishore et al., 2010], that on the opposite can destabilize proteins. During 
freeze-thawing PS-80 protects proteins by hindering destructive interactions with ice-
crystals [Hillgren et al., 2002]. The existence of PS-80 is influencing the appearance 
of protein particles.  
Summarizing the comparison of MFI and LO revealed that MFI is very sensitive for 
detection of translucent protein particles, as already addressed in literature [Huang et 
al., 2008; Sharma et al., 2010]. Proteins are prone to aggregation and obviously 
many protein formulations are generating translucent particles during stress, not 
detectable with LO. Hence, MFI is a valuable instrument for protein aggregate 
quantification. The microflow imaging method should be further evaluated with the 
view to adapt pharmacopoeial methods. 
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3.4 Conclusion 
The scientific community has started a discussion about the gaps in analytical 
assessment of protein solutions [Carpenter et al., 2008; Giezen et al., 2008; Singh et 
al., 2010]. Development of more sensitive tools was postulated to close the gap. In 
that course the new instrument AccuSizer FY nano® theoretically able to measure in 
the range >150 nm and Microflow Imaging DPA 4200 were assessed.  
From the present results it is evident that counting particles <1 µm with AS is not as 
promising as expected due to the high background noise. Although DLS and SEC 
measurements showed changes in the nanometer range after thermal stress, AS did 
not detect any protein denaturation. Indeed it is possible to detect particles in the 
range >150 nm using particle size standards, however counting is not accurate. 
A potential particle count increase is covered with high particle counts from 
background noise. The nominal lower detection limit of 150 nm could not be 
confirmed with the described experiments. A lower size limit of 750 nm can be 
provided which is not far from the lower size limit of the classically used light 
obscuration instruments. Previous work in this field [Mück, 2002] showed that also 
instruments with electrical sensing zones (Coulter Counter) can not provide the 
nominal lower detection limit due to high background noises. Early events of 
aggregation could only be detected at 700 nm which is close to the detection limit of 
our experiments and also close to the lower detection limit of light blockage 
instruments. Regarding the new AccuSizer FY nano® instrument there is reasonable 
suspicion that light blockage detector is operating and counting well, whereas light 
scattering detector is not adequate for counting particles within performed 
experiments. 
Results from particle counting with MFI delivered slightly more information with 
regard to subvisible particles than particle counting with classical LO. Particles 
formed during mechanical stress and freeze-thawing from an IgG1 formulated with 
PS-80 are different to those formed during freeze-thawing and mechanical stress 
from proteins not protected with PS-80. Proteins formulated without PS-80 form both 
translucent and dense particles during stress, therefore MFI is more sensitive than 
LO. IgG1 under PS-80 protection forms consistently dense and dark particles which 
are perfectly detectable with LO. 
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USP <788> is requiring not to have more than 6000 particles ≥10 µm and more than 
600 particles ≥25 µm in a container. There is reason to think that this is too 
insensitive. Former studies figured out, that particles ≥1 µm and ≥10 µm were 
detected at absolutely the same time [Singh et al., 2010]. However, results from this 
study show that a correlation between particle formation in the size classes in the 
USP-required ranges and particle formation in the size ranges ≥1 µm/≥750 nm is 
depending on the protein. Stressing sensitive proteins, leads to an earlier formation 
of smaller particles than of larger ones. Antibodies did confirm the mentioned studies 
from Singh: particles in size classes ≥1 µm and ≥10 µm were detected at the same 
time. 
There is also evidence for the fact that e.g. stirring shears larger particle to smaller 
ones. We found, that particles ≥10 µm built by freeze-thawing are crushed into 
smaller ones after stirring even at low stirring speeds (e.g. 400 rpm); altering of large 
particles to smaller ones over storage time was found recently [Kiese et al., 2010].  
Stirring at higher speeds (600 rpm or 700 rpm) leads to faster crushing of large 
particles. This implies that stir stress experiments lead to large amounts of smaller 
particles but not to “out-of-specification” results. Increasing amount of larger particles 
would occur after long and faster stirring; though small particles are already existent 
after short time or lower stir speed. An aggregated protein solution could therefore 
also pass the USP requirements, when large aggregates have been crushed to 
smaller ones during stirring. 
 
For the time being, it is recommendable to use classic light obscuration (10 µm) in 
combination with SEC [den Engelsman et al., 2011]. This allows in all cases studied 
most sensitive analytic for the moment. However, e.g. crushing large particles into 
smaller ones during stirring makes it reasonable to reconsider pharmacopoeial 
requirement sooner or later. Stirring is an essential manufacturing step; the formed 
smaller particles are not assessed within the guidelines. 
For the future it is recommended to include MFI measurements in the ranges ≥1 µm 
as standard requirements into pharmacopoeias. MFI measurements deliver more and 
earlier information about beginning protein aggregation; MFI is a helpful and 
informative method. 
Measurements in the submicron range of AccuSizer do not lead to higher sensitivity 
and relevant more information with available equipment.  
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4. Dilution of Stressed Protein Solutions into Serum: 
Effects on Particle counting 
4.1 Introduction 
Proteins are mainly administered subcutaneously or intravenously. In both cases, it is 
obvious that colloidal stability and other factors determining the quality of the drug will 
change after administration compared to the situation in vitro, i.e. in the formulation. 
Typically such effects are neglected as due to dilution on the one hand and the fact 
that the respective body fluids represent aqueous buffer systems no immediate risk 
exists on the other. However, in certain cases formulations with non-physiological pH, 
very high or low ionic strength, or solvent content precipitation of the drug either 
immediately or soon after the injection should be considered. Such effects might 
affect pharmacokinetics and/or lead to immunologically relevant complications [Buttel 
et al., 2011; Schellekens, 2005]. Proteolytic enzymes can also alter protein’s efficacy. 
Alternatively dissolution of aggregates and particulate matter in the formulated drug 
product may take place and may render compromised in vitro quality attributes rather 
irrelevant in vivo.  
In the scientific community discussions have started about the right track to deal with 
aspects of advanced formulation assessment in future [Jiskoot et al., 2011]. Different 
analytical approaches were chosen, aiming to characterize the fate of therapeutical 
proteins in physiological fluids. However, e.g. results regarding adsorption of serum 
components onto therapeutical proteins are not clear yet. Further studies found 
similar sedimentation coefficients for IgE in PBS and serum, suggesting that binding 
of serum components to IgE was very small or even not existing [Demeule et al., 
2009]. Other studies, using fluorescence single particle tracking, discovered that 
serum components seemed to adsorb to protein aggregates [Filipe et al., 2011].  
In this study, we wanted to evaluate the potential of particle counters to determine 
protein particles in physiological media. Serum solutions with its yellowish 
appearance might diminish the possibility that particles are detected as particle 
counting relies on a sufficient difference of refractive index between particle and 
surrounding medium. Furthermore, particle counting is evaluated to follow the fate of 
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aggregated therapeutical proteins in different media, such as serum solution. Particle 
counts of stressed therapeutical proteins were monitored over 20 hours to judge 
whether there is an adsorption of serum components accompanied with increasing 
particle counts. In fact, proteins are not expected to circulate unmodified up to 20 
hours in blood [Yoo et al., 2010]. They are opsonised by macrophages before. 
However, in a first approach contact of therapeutical proteins and serum is allowed 
for 20 hours to study all possible changes and adsorptions.  
In a first approach we studied the effects of dilution into serum solution and reference 
buffer solutions on particulate matter in IgG1-α-solutions. Therefore, protein solutions 
were stressed mechanically, thermally or by freeze-thawing and stressed samples 
were diluted 1:50 into serum solution (pH 7.4) and buffer solutions (matching 
formulation buffer and phosphate buffer at pH 7.4). Samples were analyzed directly 
after dilution and after up to 20 h incubation times. 
4.2 Experimental setup 
Serum solution containing 10 mg/ml bovine serum albumin (BSA) in 5 mM phosphate 
buffer at 7.4 was prepared; matching placebo buffer was also prepared at pH 7.4. 
Phosphate buffer concentration was chosen according to physiological conditions 
[MedizInfo, 2011]: human blood contains 0.5 mM phosphate buffer; as it was not 
possible to simulate haemoglobin buffer and bicarbonate buffers, phosphate buffer 
concentration was chosen 10-fold higher as found in human blood. 
The formulations of three therapeutic proteins (IgG1-α (5 mg/ml), GCSF (0.5 mg/ml) 
and rPA (1.0 mg/ml)) were filtered through a 0.2 µm Millex syringe-driven filter unit 
(Millipore, Carrigtwohill, Ireland) into a particle free beaker and filled into particle free 
vials. 
The protein samples were submitted to different stresses: freeze-thawing, 
mechanical and thermal stress. Stressed protein was diluted 1:50 into different 
(physiological) media: corresponding formulation buffer, BSA in phosphate buffer at 
pH 7.4 (“serum solution”), or phosphate buffer at pH 7.4 (each n = 3).  Each sample 
with stressed protein in different media was analyzed after 0 and 20 hours (figure 1) 
using LO and MFI. The dilution step was performed to simulate the administration of 
comparably small amounts therapeutical protein into large amounts of serum.  
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Fig. 1: Experimental setup 
 
IgG1 (pH 6.0), GCSF (pH 4.0) or rPA (pH 7.2) 
Stress (shaking, heating or freeze-thawing) 
Formulation buffer          
pH 6.0, pH 4.0 or pH 7.2
Phosphate buffer pH 
7.4
Serum solution 
pH 7.4 
t0 hours t20 hoursStanding times:
Dilution 1:50 into 
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4.3 Results and discussion 
Particle counting was performed using LO and MFI. Three vials per sampling point 
(0 and 20 hours) were analyzed; each with one measurement performed with MFI, 
two measurements with LO. First run of LO was taken as rinsing. We compared 
particle counts for both instruments at t0 and t20 for particles ≥1 µm and ≥10 µm. 
Furthermore, standard deviations were considered into interpretations with regards to 
changes or trends: Small standard deviations and clear particle count decrease or 
increase was considered as a change. In case standard deviations were high, raw 
data were checked. If one outlier differed strongly and seemed unreasonable, a 
change in particle counts over time although not statistically significant was then 
claimed as a change. Strongly differing values pointed only to a trend. 
If not further mentioned, graphs show particle counts after dilution of therapeutic 
protein into serum or buffer solutions. 
4.3.1 Mechanical stress and dilution of IgG1 
 
Fig. 2: LO results after dilution of mechanically stressed IgG1-α into serum-solution (dark grey), 
phosphate buffer (light grey) and formulation buffer (white);  
A: particles ≥1 µm/ml B: particles ≥10 µm/ml 
 
Stressing IgG1-α mechanically and diluting into different media delivered surprising 
results: Dilution into phosphate buffer at pH 7.4 led to a strong decrease in particle 
count over time for all particle size classes, whereas particles diluted into serum-
solution (pH 7.4) tend to increase and particles diluted into formulation buffer (pH 6.0) 
were more stable (figure 2). Particle count in serum-solution and formulation buffer 
did not change significantly. Same results were found for MFI measurements (data 
not shown).   
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The phenomenon of decreasing particle count in phosphate buffer was scrutinized in 
chapter 5 (Buffer-screening: Effects of dilution, pH and standing time on particulate 
matter in IgG1-solution). 
4.3.2 Freeze-thawing and dilution of IgG1 
Freeze-thawing IgG1-α and diluting the stressed samples into the three different 
media resulted in a decrease of particle counts over 20 hours in all size classes, 
except particles ≥10 µm in serum-solution. According to LO results, particle counts 
for these particles increased over 20 hours (figure 3A/B). 
MFI measurements did not show any trend (figure 3C/D). Particle in all tested media 
at both particle size classes seemed to be stable. 
 
Fig. 3: LO (upper serial; A/B) and MFI (bottom serial; C/D) results after dilution of freeze-thawed IgG1-α 
into serum-solution (dark grey), phosphate buffer (light grey) and formulation buffer (white) 
A/C: particles ≥1 µm/ml B/D: particles ≥10 µm/ml 
4.3.3 Mechanical stress and dilution of GCSF 
GCSF particles formed during mechanical stress showed different trends. Whereas, 
LO measurements revealed a decrease in particle counts for particles in all tested 
media and all particle size classes over time (figure 4A/B), MFI results showed 
different changes: particle counts (≥1 µm and ≥10 µm) significantly increased during 
20 hours in serum (figure 4C/D). Particle counts (≥1 µm) in phosphate buffer and 
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formulation buffer showed an increasing trend over time (figure 4C). Particle counts 
(particles ≥10 µm) in phosphate buffer and formulation buffer did not show any 
changes. It is already reported in literature that MFI is more sensitive with regards to 
translucent particles than LO. A minimal refractive index difference between protein 
particle and solution medium is required for particle detection with both instruments. 
The required difference for MFI is smaller than for LO [Huang et al., 2008; Sharma et 
al., 2010a; Sharma et al., 2010b]. It is already discussed in literature that MFI is much 
more sensitive to translucent particles than LO [Barnard et al., 2012; Huang et al., 
2008; Mire-Sluis et al., 2011; Sharma et al., 2011; Sharma et al., 2010a]. Particles 
formed by mechanically stressed GCSF became translucent over time (figure 4); 
therefore they were not detectable any more using LO, whereas MFI could still detect 
an increase of particles in serum solution. Figure 5 shows examples of pictures found 
after mechanical and freeze-thaw stress of GCSF. After a standing time of 20 hours, 
particles became more translucent, as already indicated with particle counting results 
of LO and MFI. 
 
Fig. 4: LO (upper serial; A/B) and MFI (bottom serial; C/D) results after dilution of mechanically stressed 
GCSF into serum-solution (dark grey), phosphate buffer (light grey) and formulation buffer (white) 
A/C: particles ≥1 µm/ml B/D: particles ≥10 µm/ml 
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Fig. 5: Examples of translucent particles found with MFI directly (t0) and 20 hours (t20) after diluting 
mechanically stressed or freeze-thawed GCSF into formulation buffer, phosphate buffer or serum solution 
4.3.4 Freeze-thawing and dilution of GCSF 
According to LO measurements, freeze-thawing GCSF and dilution into serum-
solution, phosphate buffer, or formulation buffer resulted in a decrease of particle 
count for all particle size classes (figure 6A/B), whereas MFI measurements did not 
show significant trends over time (figure 6C/D).  
However, a trend towards decreasing particle counts found in formulation buffer for 
both particle size classes could be detected, whereas particle counts in serum-
solution and phosphate buffer were more or less the same after 20 hours. Again, 
stressed GCSF particles became more translucent in all tested media and particle 
size classes (see also figure 5).  
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Fig. 6: LO (upper serial) and MFI (bottom serial) results after dilution of freeze-thawed GCSF into 
serum-solution (dark grey), phosphate buffer (light grey) and formulation buffer (white) 
A/C: particles ≥1 µm/ml B/D: particles ≥10 µm/ml 
 
In summary, particle formation and resulting particle count increase can be found 
after diluting stressed GCSF solution into serum-solution. Particles becoming 
translucent, clearly confirmed with MFI. Diluting stressed GCSF solution into 
phosphate buffer or formulation buffer did not show increasing particle counts. 
Particles were stable or showed a decreasing trend in count.  
The fact, that protein particles become translucent over time and can not be detected 
with LO but only with MFI is alarming, as particle count measurements according to 
pharmacopoeias is performed using e.g. classical LO. Protein particles might be 
overlooked. 
4.3.5 Mechanical stress and dilution of rPA 
Mechanical stress of rPA and dilution into the different media again showed different 
trends and changes (figure 7).  
LO measurements showed a decrease in particle counts (≥1 µm) in formulation 
buffer (figure 7A) and also decreasing particle counts (≥10 µm) in all tested media 
(figure 7B), whilst small particles in serum and phosphate buffer are clearly 
increasing. MFI measurements revealed no changes for particles ≥1 µm in all media 
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(figure 7C) and for particles >10 µm in formulation buffer, whereas larger particles in 
serum-solution and phosphate buffer are increasing (figure 7D). Consequently, 
smaller particles are becoming less translucent and more dense over time, whilst 
larger particles are becoming more transparent (figure 7), only detectable using MFI 
(figure 8). 
 
Fig. 7: LO (upper serial) and MFI (bottom serial) results after dilution of mechanically stressed rPA into 
serum-solution (dark grey), phosphate buffer (light grey) and formulation buffer (white) 
A/C: particles ≥1 µm/ml B/D: particles ≥10 µm/ml 
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Fig. 8: Examples of translucent particles found with MFI directly (t0) and 20 hours (t20) after diluting 
mechanically stressed or freeze-thawed rPA into formulation buffer, phosphate buffer or serum solution 
 
4.3.6 Freeze-thawing and dilution of rPA 
Freeze-thawing and diluting rPA-samples delivered another trend in particle 
formation. LO measurements for particles ≥1 µm showed a decrease over 20 hours 
in phosphate and formulation buffer, whereas particles in serum-solution seemed to 
be more stable and showed no differences in count over time (figure 9A).  
Larger particles did also show a decrease in particle count (figure 9B). According to 
MFI results, larger particles showed no differences in count over time (figure 9D) and 
consequently became more translucent (see figure 8). Particles ≥1 µm in formulation 
buffer decreased and particles in serum increased and also became more 
transparent (figure 9C). 
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  Mechanically stressed rPA; 
diluted in phosphate buffer 
  Mechanically stressed rPA; 
diluted in formulation buffer 
  Freeze-thawed rPA; 
diluted in Serum 
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Fig. 9: LO (upper serial) and MFI (bottom serial) results after dilution of freeze-thawed rPA into serum-
solution (dark grey), phosphate buffer (light grey) and formulation buffer (white) 
A/C: particles ≥1 µm/ml B/D: particles ≥10 µm/ml 
 
Summarizing, particle counts detected with LO decreased over time in all tested 
media, except small particles found after mechanical stress and dilution into serum 
solution and phosphate buffer at pH 7.4. Particle counts detected with MFI were more 
stable or increased in serum and phosphate buffer over time. Particles again became 
more translucent over time, except small particles after mechanical stress diluted into 
serum solution and phosphate buffer, which became less translucent. Particle counts 
of particles ≥10 µm in serum solution and phosphate buffer even increased over time. 
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4.3.7 Thermal stress  
Heating IgG1-α-solution and diluting it into the three media resulted in a clear particle 
count decrease in all size classes and all media (figure 10A/B).  
As thermally stressed IgG1-α forms covalently linked aggregates particle redissolving 
was not expected [Hawe et al., 2009]. MFI results showed no clear trend in decrease 
or increase of particle counts (data not shown).  
Heating and diluting GCSF did not deliver any trends in decrease or increase of 
particle counts using LO and MFI (data not shown). 
 
 
Fig. 10: LO results after dilution of thermally stressed IgG1-α into serum-solution (dark grey), phosphate 
buffer (light grey) and formulation buffer (white) 
A: particles ≥1 µm/ml B: particles ≥10 µm/ml 
 
Heating and diluting rPA resulted in a decrease of particle counts (≥1 µm) in all 
media and for both instruments, LO and MFI (figure 11A/C). Information regarding 
particle counts for particles ≥10 µm differed: LO measurements resulted in a particle 
count decrease (figure 11B), whereas MFI measurements resulted in a particle count 
increase (figure 11D).  
The expectation was that particles are becoming more translucent as seen for 
mechanical and freeze-thaw stress. Surprisingly, standing times after thermal stress 
resulted in dense and dark particles, which should have been detectable with LO. 
The dense particles mainly have been detected after diluting into serum and 
phosphate buffer at pH 7.4 (figure 12). Obviously, particle counters do not give 
consistent information after thermal stress, as already mentioned in chapter 3. 
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Fig. 11: LO (upper serial) and MFI (bottom serial) results after dilution of thermally stressed rPA into 
serum-solution (dark grey), phosphate buffer (light grey) and formulation buffer (white) 
A/C: particles ≥1 µm/ml B/D: particles ≥10 µm/ml 
 
 
Fig. 12: Examples of particles found with MFI directly (t0) and 20 hours (t20) after diluting mechanically 
stressed or freeze-thawed rPA into formulation buffer, phosphate buffer or serum solution 
  Thermal stressed;  
diluted in Serum 
  Thermal stressed; 
diluted in Phosphatebuffer 
  Thermal stressed;  
diluted in Placebo 
 
t20 
 
t0 
 
0
1000
2000
3000
4000
5000
6000
7000
8000
t0 t20
Pa
rt
ic
le
 c
ou
nt
s 
≥1
 µ
m
/m
l
0
50
100
150
200
250
300
350
t0 t20
Pa
rt
ic
le
 c
ou
nt
s 
≥1
0 
µm
/m
l
0
20000
40000
60000
80000
100000
t0 t20
Pa
rt
ic
le
 c
ou
nt
s 
≥1
 µ
m
/m
l
0
100
200
300
400
500
600
700
800
900
1000
t0 t20
Pa
rt
ic
le
 c
ou
nt
s 
≥1
0 
µm
/m
l
A B
C D
 92 
4.3.8 Kinetics 
In the described experiments we investigated trends in particle counts after 20 hours. 
The results are in fact very interesting. However, proteins are not circulating 20 hours 
in human blood. Therefore, we studied the trend after one, two and four hours for a 
selected set of experiment. 
Examining mechanical stress of rPA and comparing figure 7 and figure 13 makes 
clear that e.g. particle count increases in serum and phosphate buffer are already 
taking place within the first hour after dilution and particle counts remaining stable 
afterwards; although it was previously published that particle equilibrium is only 
adjusted after months of storage [Kiese et al., 2010].  
 
 
Fig. 13: Kinetic. LO (upper serial) and MFI (bottom serial) results after dilution of mechanically stressed 
rPA into serum-solution (dark grey), phosphate buffer (light grey) and formulation buffer (white) 
A/C: particles ≥1 µm/ml B/D: particles ≥10 µm/ml over time 
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4.4 Conclusion 
One aim of this study was the evaluation of potential of particle counters to determine 
protein particles in physiological media. Particle counting was absolutely possible 
with both tested particle counters: LO and MFI. Presence of serum had no influence 
on the measurements. 
The main aim of this study was to assess the fate of protein particles after dilution 
into different (physiological) media. To simulate the administration into humans, 
stressed protein solutions were diluted 1:50 into different media. In order to have 
enough protein particles after dilution, the proteins had to be extremely stressed. 
During measurements of undiluted solutions the detection limit of the particle 
counters was reached.  
We can not draw clear conclusions regarding the adsorption of serum components to 
pharmaceutical protein particles and accompanied increasing aggregate counts. The 
aggregate counts after administration into serum solutions increased, which can 
mean that protein aggregates may trigger further aggregation or serum may bind to 
studied proteins. However we can not exclude effects like pH changes, as particle 
counts also increase after dilution into phosphate buffer. The possibility of serum 
components to adsorb onto protein particles was already studied by analytical ultra 
centrifugation [Demeule et al., 2009]. The sedimentation coefficient in serum and in 
PBS was found to be similar, which points to the fact that serum components are not 
binding to the therapeutic antibody studied. However, different results were found in 
other studies: interactions between and adducts of therapeutic proteins and human 
serum albumin were found, verified by ELISA [Braun et al., 1997; Kumarasamy et al., 
1994]. 
 
From our results it can be further concluded that particulate matter in aggregated 
protein solutions may change after dilution into different (physiological) media: 
obviously, a significant amount of preformed aggregates is redissolved; other 
aggregates grow further, particularly in serum. Consequently, aggregation is still 
relevant with regards to dilution in vitro or in vivo. After dilution into phosphate buffer 
or placebo the situation may be different due to changes of pH and ionic strength 
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[Sahin et al., 2010], time [Kiese et al., 2008; Kiese et al., 2010], or pure dilution 
effects [Carpenter et al., 2009]. However, for simulations of proteins administration 
into human body only serum solution effects were of utmost interest for us.  
Three different proteins were tested in this study: IgG1, GCSF and rPA. Particularly 
GCSF and rPA are susceptible to stress; particles formed from these two proteins 
were becoming translucent over time and the particle count increased. These 
particles were only detectable using MFI. Particles formed by IgG1-α were more 
stable and the particle count did not further increase. Formed particles did not show 
the tendency to become translucent over time and were detectable with MFI and LO 
after 20 hours. 
 
From the first experiments with IgG1-α solution it was concluded that aggregation 
after typical in vitro stress tests might not be overly relevant when such formulations 
are diluted in vitro or in vivo. However, studying GCSF and rPA as further proteins, 
these conclusions have to be revised and change to the opposite. We found 
increasing particle counts and increasing particle transparency after dilution of 
stressed protein solutions into physiological media. The fact, that protein particles 
can become translucent over time is alarming. Particle counts are currently monitored 
with e.g. classical LO, while translucent particles can only be detected with MFI. This 
means in reverse, that aggregation of proteins has to be avoided in any case as the 
aggregates are not redissolved after administration into human body but even 
increased. 
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5. Buffer-Screening: Effects of Dilution, pH and 
Standing Time on Particulate Matter in 
IgG1-Solution 
5.1 Introduction 
As described in Chapter 4 (“Dilution of stressed protein solutions into serum: Effects 
on particulate matter“) decreasing particle counts could be found when diluting 
mechanically stressed IgG1-α particles into serum-buffer (phosphate-buffer) at pH 7.4 
over time. However, particles were more stable when diluted into formulation buffer at 
pH 6.0. It is already reported in literature that buffers can have an immense effect on 
proteins [Katayama et al., 2006]. 
This buffer-screening is intended to investigate the effects of dilution, pH, ionic 
strength, and standing time on particulate matter in an IgG1-α-solution. All factors are 
reported in literature to have a strong effect on protein solution [Carpenter et al., 
2009; Kiese et al., 2010; Sahin et al., 2010]. Phosphate-buffers at pH 4.0 (acidic pH), 
pH 6.0 (formulation pH of IgG1-α-solution) pH 7.0 (close to physiological tissue pH) 
and pH 9.0 (close to isoelectric point = pH 8.81) were chosen, each at ionic strengths 
of 10 mM or 75 mM according to chapter 4. Mechanical stress was applied on the 
IgG1-α-solution and consequently stressed samples were diluted 1:50 into phosphate 
buffers (experiment 1). In a further experiment (experiment 2), IgG1-α-solution was 
first diluted 1:50 into the different phosphate buffers and then stressed mechanically. 
In both experiments standing times from 0 to 48 h were applied until particle counting 
was performed. 
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5.2 Experimental setup 
The protein formulation (IgG1-α) was filtered through a 0.2 µm Millex syringe-driven 
filter unit (Millipore, Carrigtwohill, Ireland) into a particle free beaker and finally filled 
into particle free Zinsser vials and sealed with screw caps (Zinsser Analytic, Frankfurt, 
Germany). 5 h shaking stress was applied at 1000 rpm. 
The protein samples were exposed to mechanical stress followed by an 1:50 dilution 
into the respective buffer.   
8 Phosphate buffers with different pH (pH 4.0 (acidic pH), pH 6.0 (formulation pH) 
pH 7.0 (close to physiological pH) and pH 9.0 (close to isoelectric point) and different 
ionic strengths (10 mM and 75 mM) were applied. 
In a first experiment, IgG1-α-solution (5 mg/ml) was mechanically stressed over 
5 hours at 1000 rpm. The stressed IgG1-α-solution was diluted 1:50 into buffers 
(n = 3) to obtain a final concentration of 0.1 mg/ml. Particle counting was performed 
using light obscuration and Microflow Imaging after 0, 24 and 48 hours. 
In a second experiment IgG1-α-solution (5 mg/ml) was diluted 1:50 into buffer (n = 3). 
Diluted IgG1-α samples (0.1 mg/ml) were mechanically stressed over 5 hours at 
1000 rpm and particles were counted after 0, 24 and 48 hours.  
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5.3 Results and discussion 
5.3.1 Experiment 1 
5.3.1.1 Results of particle counting: LO and MFI 
LO measurements resulted in decreased particle counts (particles ≥1 µm) over time 
for all tested pH-values and ion concentrations (figure 1 A/C). This effect is even 
stronger at alkaline pH. In parallel, particle counts (particles ≥10 µm) increased over 
time (figure 2 B/D). Small particles grow into larger ones, which is more pronounced 
at alkaline pH and higher buffer molarity. 
However, different information is obtained from MFI measurements. MFI particle 
count measurements were not as consistent as LO measurements (figure 2). Particle 
counts slightly decreased over time (particles ≥1 µm and ≥10 µm, both ionic 
strengths). Furthermore, fewer particles were found at alkaline pH and high ionic 
strengths.  
 
Fig. 1: Light obscuration results for experiment 1: stressed sample was diluted in different phosphate 
buffers and measurement was performed after 0 (dark grey), 24 (light grey) and 48 (white) hours 
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Fig. 2: Micro-flow Imaging results for experiment 1: stressed sample was diluted in different phosphate 
buffers and measurement was performed after 0 (dark grey), 24 (light grey) and 48 (white) hours 
 
 
Fig. 3: Microflow-Imaging results (Intensity mean) for experiment 1: stressed sample was diluted in 
different phosphate buffers and measurement was performed after 0, 24 and 48 hours 
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bubbles, and large edge particles. Air bubbles are known to be circular; therefore all 
detected particles with a circularity ≥0.85 were excluded [Sharma et al., 2009]. Large 
edge proteins are often stuck to the flow cell and detected more than once, therefore 
all detected particles ≥ 80 µm were also excluded. Recently, the development of an 
improved filter was reported [Strehl et al., 2011]. 
Low intensity mean values are found at alkaline pH. IM values decrease over time, 
which suggests that particles become denser, further particles are denser at alkaline 
pH. This explains the comparable low particle count (particles ≥1 µm) detected with 
LO at pH 4.0 (t0): particles are too translucent to be detected with LO (figure 1A/C).  
5.3.1.2 Effect of dilution on pH 
After dilution of serum into buffer solutions, pH was controlled (table 1). The buffer 
capacity of the higher molar buffer is clearly noticeable: pH values were kept almost 
constant. Diluting the small amount of IgG solution 1:50 into the 10 mM buffers, only 
the pH value within the neutral buffer was kept constant, whereas acidic pH values 
slightly increased and alkaline pH values decreased. This implies that pH values 
given for the low molecular buffers in figures 1 and 2 are slightly different from stated 
pH values.  In lower molar buffers, the pH differences are not as strong as in higher 
molar buffers; this explains the stronger effect of the higher molar buffer on the 
dilution of smaller particles. 
 
Table 1: pH values after pH adjustment of buffers (buffer) and directly after addition of stressed IgG 
solution (controlled) 
    pH 4 pH 6 pH 7 pH 9 
10mM buffer 4.06 6.05 6.86 8.72 
  controlled 4.45 6.20 6.86 8.10 
75mM buffer 3.84 5.93 6.72 8.69 
  controlled 3.92 5.99 6.73 8.42 
 
5.3.1.3 Dilution effect on particulate matter 
To evaluate the influence of dilution, mechanically stressed and undiluted samples 
are measured as control (table 2). The particle numbers after dilution (table 3) were 
compared with the particle numbers before dilution. To recalculate the 1:50 dilution, 
the particle numbers before dilution were divided by 50, printed in bold. It is obvious, 
that for particles ≥1 µm the detection limit has been reached: all diluted samples 
reveal a higher particle count than undiluted and recalculated samples. Hence, for 
small particles an assessment regarding the dilution effect is not possible. For larger 
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particles the result is different: the undiluted and recalculated solution exposes a 
higher particle count than diluted samples. This implies that larger particles are 
dissolved immediately upon dilution. 
 
Table 2: Particle counts and standard deviations after mechanical stress; undiluted and recalculated 
samples 
  Undiluted Undiluted, divided by 50 
Particles ≥1µm/ml 166283 ± 7943 3326 
Particles ≥10µm/ml 26621 ± 4429 532 
 
Table 3: Particle counts and standard deviations after mechanical stress and dilution in respective buffers  
    Diluted in 10 mM buffer Diluted in 75 mM buffer 
Particles ≥1µm/ml pH 4 6571 ± 730 8573 ± 1703 
  pH 6 12814 ± 1171 11375 ± 2062 
  pH 7 16091 ± 1833 11557 ± 1475 
  pH 9 14880 ± 2455 11980 ± 666 
Particles ≥10µm/ml pH 4 1 ± 1 4 ± 1 
  pH 6 19 ± 5 25 ± 3 
  pH 7 55 ± 9 4 ± 1 
  pH 9 33 ± 9 11 ± 5 
 
5.3.1.4 Zeta potential measurements 
Summarizing, the different information between LO and MFI results have to be 
further evaluated.  
In a first approach, zeta potential (ZP) theory is dedicated to clarify results. In theory, 
close to isoelectric point (IEP) ZP values are low [Chiti, 2006; Jachimska et al., 2008], 
the protein carries no net charge, and van der Waal’s forces are outweighing and 
protein particles tend to aggregate [Calamai et al., 2003; Chiti et al., 2006]. Zeta 
potential is strongly dependent from pH: at acidic pH zeta potential is positive, at 
more alkaline pH zeta potential values become negative and at IEP zeta potential is 
zero [Arakawa et al., 1984; Ruppert et al., 2001] as schematically shown in figure 4. 
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Fig. 4: Zeta potential (ZP) theory as a function of pH 
 
Practically, ZP titrations should be performed at protein concentrations of 4-10 mg/ml 
and ionic strengths of maximum 20 mM.  Hence, ZP titrations of diluted samples 
(0.1 mg/ml) were not possible, as well as titration in 75 mM phosphate buffer. 
Therefore ZP of IgG1-α was measured in bulk concentration (5 mg/ml) after buffer 
exchange to 10 mM histidine at pH 6.0 (figure 5), which is the formulation buffer. 
 
Fig. 5: Zeta potential (5 mg/ml IgG1 in 10 mM histidine pH 6.0) as a function of pH 
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Theoretically, at pH 8.81 net charge of protein is zero and aggregation of particles is 
predominant over repulsion. 
On the one hand, LO measurements perfectly fit in: particle counts for particles 
≥1 µm increased with increasing pH at t0. Particle counts for particles ≥1 µm/ml at t1 
and t24 are smaller at pH 9.0 than at pH 4.0, however, particles ≥10 µm/ml are 
increasing with increasing pH. Smaller particles seem to aggregate to larger ones 
close to IEP. On the other hand, results of MFI measurements show a particle count 
decrease close to IEP not explainable with ZP theory. Furthermore, it seems that 
aggregates are even redissolving close to IEP, where the protein solution is 
theoretically most instable and aggregation should be predominant. MFI results show 
a particle count decrease with increasing pH for both particle size classes. 
Interestingly, IM is increasing with increasing zeta potential (figure 6). This implies 
that particles are more translucent with increasing zeta potential and increasing 
stability of solutions. The less the solution stability is, the denser protein particles are.  
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Fig. 6: Intensity mean as a function of zeta potential: Found IM values for 10 mM and 75 mM are plotted 
over zeta potential values from titrations after buffer exchange (see above) 
 
It is already addressed in literature that MFI is more sensitive to transparency of 
particles [Huang et al., 2008; Sharma et al., 2011; Sharma et al., 2010]. 
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However, in this case MFI obviously is not detecting particles that are expected due 
to zeta potential theory [Chiti, 2006; Jachimska et al., 2008] and also are detected by 
LO.  
 
5.3.1.5 Microscopic results 
Zeta potential titrations offered valuable clues on protein aggregation dependencies, 
however, it has not been clarified yet, whether particle counts from LO or MFI has to 
be conceded as true. An important difference to examine is the increasing (LO; 
figure 1 B/D) respectively decreasing (MFI; figure 2B/D) particle count of larger 
particles over time. 
Stressed protein was diluted into phosphate buffer at pH 4.0 and pH 9.0 at both ionic 
strengths, further characterization was performed at t0 and t24. 
 
Fig. 7: Microscope pictures of stressed IgG1-α diluted into phosphate buffer at pH 4.0 
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experiment not the absolute particle number but a trend of particle counts decrease 
or increase over time should be evaluated.  
Microscope pictures confirmed IM results found with MFI: particles at pH 4.0 at both 
ionic strengths are more translucent than particles at pH 9.0 at both ionic strengths.  
Also IM values are higher at acidic pH, proving particles at pH 4.0 to be translucent. 
Further, microscope pictures confirm the trend for particles ≥10 µm found with LO 
and ZP theory: larger particles are increasing over time. Figure 7 and 8 show 
particles of diluted protein samples at t0 and t24. Both figures show an increasing 
trend for particles, more pronounced at pH 9.0 (figure 8), which fits to LO results. 
Of course, as samples are neither filtered nor proteinacious particles are selectively 
stained, this trend has to be examined with caution. MFI results are not explainable, 
especially as for pilot experiments in chapter 4 MFI showed same results as LO. 
 
Fig. 8: Microscope pictures of stressed IgG1-α diluted into phosphate buffer at pH 9.0 
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5.3.2 Experiment 2 
5.3.2.1 Results of particle counting: LO and MFI 
In general, stressing diluted protein solutions does not lead to high amounts of 
aggregates as protein monomers are not crossing each others ways often [Shire et 
al., 2004]. Therefore, experiment 2 does not lead to comparable particle counts as 
experiment 1.  
 
 
Fig. 9: Light obscuration results for experiment 2: diluted sample was stressed in different phosphate 
buffers and measurement was performed after 0 (dark grey), 24 (light grey) and 48 (white) hours 
 
LO measurements revealed high standard deviations after mechanical stress 
(figure 9). Particle counts for particles ≥1 µm and ≥10 µm found in 10 mM samples 
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LO measurements in 75 mM samples discovered even higher standard deviations 
than in 10 mM samples in both particle size classes. However, there are still same 
trends observable: particle counts seem to increase after 24 hours and to decrease 
again after 48 hours. The particle level is higher than in 10 mM samples. Particle 
counts seem to increase (not significantly) with increasing pH. 
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Fig. 10: Micro-flow Imaging results for experiment 2: diluted sample was stressed in different phosphate 
buffers and measurement was performed after 0 (dark grey), 24 (light grey) and 48 (white) hours 
 
 
MFI measurements also showed high standard deviations, especially in the 75 mM 
samples (figure 10). For the 10 mM samples particle levels were low, there is also the 
trend of increasing and then decreasing particle count over time. In 75 mM samples 
particle count is also low for particles ≥1 µm, except at pH 9.0. In these samples high 
amounts (~400000) of small particles were found, also visible with LO.  
 
However, in general LO and MFI results of experiment 2 fit to zeta potential theory: 
particle counts are increasing with increasing pH. Close to IEP more particles are 
found than at acidic pH at which the protein solution is more stable. 
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5.4 Conclusion 
Stressing diluted solutions does not result in high amounts of aggregates. Amongst 
other reasons, protein aggregation is strongly dependent on protein concentration 
[Minton, 2005; Shire et al., 2004]. Therefore, experiment 2 (applying stress on diluted 
protein solutions) is not appropriate to determine effects of different pH, standing 
times and dilution of proteins. However, one trend was dominant: particle counts 
seemed to increase first and then decrease again over time. Further, close to IEP 
particle count is higher than at larger zeta potential values. 
 
Stressing IgG1-α bulk solution, diluting it into different phosphate buffers and 
monitoring the effect of time, ionic strength and pH delivered interesting results. 
Particles ≥1 µm decrease over time and increasing pH, whilst larger particles ≥10 µm 
increase at the same time, confirmed by microscopic experiments. Concluding, the 
small particles grow into larger ones. This effect is more pronounced at alkaline pH, 
as well as higher buffer molarities. At acid pH larger particles are dissolved. IEP is 
determined at pH 8.81; protein particles are not charged and tend to aggregate and 
form larger particles. MFI results show that alkaline pH values dissolves particles, 
whereas the more acidic pH values more or less do not have any effect. These 
results could not be confirmed with orthogonal methods.  
Generally we can conclude that at pH 4.0 used IgG1-formulation is prevented from 
aggregation due to large positive zeta potential values and involved repelling forces. 
Worst pH is alkaline pH 9.0 close to IEP. Proteins are charged less and aggregate 
with each other.  Changing the pH has a huge impact on protein particles: at a pH 
value close to IEP aggregation is predominant over dissolving. At other pH values 
protein particles can be redissolved.  
Dilution of mechanically stressed protein solution directly leads to redissolving of 
larger particles. The impact of dissolution on smaller particles could not be assessed 
with these experiments as the detection limit of LO was reached.  
 
MFI-images of samples were analyzed for mean intensity (proportional to 
transparency). Intensity of particles is described in illumination intensity levels [Huang 
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et al., 2008]. Earlier it was found that intensities of proteinaceous particles differ as a 
function of size and mode of generation [Sharma et al., 2010]. These studies show 
intensity as a function of pH and time. Mean intensity decreases over increasing pH 
and also over time.  
With increasing zeta potential intensity mean is also increasing. Particles are more 
translucent at stable formulations and denser close to IEP. Close to IEP particles 
tend to aggregate. Hence, the more stable aggregates are, the denser they appear.  
 
 
The studies described within chapter 5 were performed to enlighten the decreasing 
particle count after diluting mechanically stressed IgG1 into phosphate buffer. As an 
overall conclusion it can be stated, that small particles diluted into phosphate buffers 
with different ionic strengths and pH values decrease over 20 hours (table 4).  
 
    5 mM 10 mM 75 mM 
pH 7.0 LO N/A decrease decrease 
  MFI N/A increase decrease 
pH 7.4 (from chapter 4) LO decrease N/A N/A 
  MFI decrease N/A N/A 
pH 9.0 LO  N/A decrease decrease 
  MFI N/A decrease decrease 
Table 4: Particle count over 20 hours after dilution into different phosphate buffers; particles ≥1 µm  
 
With increasing ionic strength and increasing pH larger particles tend to increase 
over 20 hours (table 5). Increasing particle count of larger particles at increasing pH 
is caused by isoelectric point at pH 8.81. Protein molecules are not charged and can 
aggregate. 
 
    5 mM 10 mM 75 mM 
pH 7.0 LO N/A decrease increase 
  MFI N/A stable decrease 
pH 7.4 (from chapter 4) LO decrease N/A N/A 
  MFI decrease N/A N/A 
pH 9.0 LO  N/A increase increase 
  MFI N/A decrease stable 
Table 5: Particle count over 20 hours after dilution into different phosphate buffers; particles ≥10 µm  
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6. Comparison of TopLyo® (Schott) Vials with 
Standard Glass Type I Vials concerning repression 
or enhancement of particle formation  
6.1 Introduction 
During protein formulation finding the most adequate packaging material is a 
challenging task. As proteins are prone to aggregation, primary packaging material 
should not be enhancing unfolding or adsorption and accompanying aggregation.  
Recently TopLyo® vials have been developed. TopLyo® vials have a hydrophobic 
coating on the inside surface. The hydrophobic surface is coated using the Plasma 
Impulse Chemical Vapor Deposition (PICVD) technique (figure 1). TopLyo® vials are 
proposed to optimize efficiency of lyophilization processes. Due to their homogenous 
hydrophobic surfaces and optimized geometry adhesion of substances and 
interactions of substances with vials is minimized. The cake after lyophilization 
should be prevented from collapsing and the residual volume is then almost 
completely reduced. 
 
Fig. 1: PICVD Coating process, developed and patented by Schott 
 
The main focus of this study lies on the evaluation of particulate matter and its 
connection to protein adsorption onto surfaces in TopLyo® vials after freeze-drying.  
On the one hand, highly chemically resistant coatings are reported to offer a benefit 
with regards to subvisible particle formation [Iacocca et al., 2010]. 
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On the other hand, hydrophobically coated TopLyo® vials theoretically make the 
proteins unfold more easily than uncoated glass vials. Freeze-drying partly removes 
the hydration layer of dried proteins and therefore disturbs protein’s native state 
[Mukherjee et al., 2009]. During freeze-drying non-covalent and covalent aggregates 
can be formed, which can be inhibited with stabilizers like sugars [Crowe et al., 1990; 
Wang et al., 2010]. During freezing non-freezable water is not removed, whereas 
drying very well removes this water, which results in changes of physical properties. 
Unfolding can be a consequence of e.g. temperature, pH change, or interfacial 
adsorption,  resulting in aggregation [Bhatnagar et al., 2007; Chang et al., 1996; 
Gomez et al., 2001; Strambini et al., 1996]. Unfolded proteins can further aggregate 
[Manning et al., 1989; Manning et al., 2010; Wang et al., 2007; Wang et al., 2010] or 
adsorb to vial surfaces [Johnston, 1996; Wu et al., 1989]. In order to reduce the loss 
of protein upon adsorption, addition of polysorbates is reported [Kueltzo et al., 2008; 
Mahler et al., 2005; Mahler et al., 2008; Wang et al., 2008]. 
The authors wanted to evaluate whether TopLyo® vials prevent or might even 
promote formation of particles during the lyophilization process. In a first approach a 
therapeutical protein (IgG1-α) and its respective placebo were filled into TopLyo® vials 
and standard glass type I vials. The protein was freeze-dried, and particle counts in 
the reconstituted solutions were taken afterwards.  
 
 
 117
6.2  Sample preparation and experimental setup 
IgG1-α solution in histidine buffer (5 mg/ml) at pH 6.0 was filtered through a 0.2 µm 
Millex syringe-driven filter unit (Millipore, Carrigtwohill, Ireland) into a particle free 
beaker and filled into particle free vials.  
3 ml protein solution was filled into TopLyo® vials and classic glass type I 5 ml vials 
(both Schott, St. Gallen, Switzerland), respective placebo solution was also filled in 
both vial types.  
20 TopLyo® and 20 classic glass vials were freeze-dried; two vials of both types were 
filled with placebo solution and were also freeze-dried. Untreated protein-formulation 
(references) was kept in both vials and stored at 2-8°C; the freeze-drying process 
was controlled using sensors in additional vials filled with protein solutions. 
After freeze-drying Karl-Fisher titrations and DSC measurements were performed 
(n = 3) to determine residual moisture and glass transition temperature of the 
samples. 
Particle counts were taken from freeze-thawed and freeze-dried samples and 
references using LO and MFI. 
Further, zeta potential titrations of the IgG1-α in 10 mM histidine buffer at pH 6.0 were 
performed, as well as protein adsorption studies. Protein adsorption studies were 
performed using the freeze-thawed samples and references. Adsorbed protein was 
desorbed using 0.05% SDS in PBS buffer at pH 7.2. The exact amount of desorbed 
protein was calculated using a 6-point calibration (0.0001-0.01 mg/ml) after SE-HPLC 
performance. The desorbed amount of protein was calculated related to the surface 
of respective vial [mg/m2]. 
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6.3 Results and discussion 
6.3.1 Physicochemical properties of lyophilizates 
Table 1 shows the residual water [%] and glass transition temperature [Duddu et al., 
1997] of the protein. It is obvious that IgG1-α and its placebo formulations do not 
show significant differences in both vial types.  
 
Table 1: Physicochemical properties of lyophilizates 
      
Protein-vial-combination Residual moisture ± SD (%)a Tg ± SD (%)b 
Placebo TopLyo® 1.25 ± 0.17 38,3 ± 1,5 
IgG1-α TopLyo® 1.25 ± 0.18 38,5 ± 1,9 
Placebo standard glass  1.12 ± 0.13 39,7 ± 10,2 
IgG1-α standard glass 1.58 ± 0.14 47,4 ± 8,05 
aDetermined by Karl Fischer titration, n = 3   
bDetermined by DSC, n = 3  
 
6.3.2 Particle counting after freeze-drying IgG1-α  
 
 
Fig. 2: Particle counting of PAMAS for a) particles ≥1 µm/ml and b) particles ≥10 µm after freeze-drying 
IgG1-α: Comparing standard vials with TopLyo® vials 
 
Particle counting using LO revealed that freeze-drying is a strong stress factor for 
IgG1-α with regards to particle formation. Indeed, it was elaborated earlier that 
antibodies can be unstable during lyophilization [Hagiwara et al., 2000]. 
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Measurements of untreated IgG1-α reference showed less than 1000 particles 
≥1 µm/ml (data not shown), whereas even freeze-dried placebo solutions contained 
more particles after freeze-drying than IgG1-α reference; particles can be 
contaminants from freeze-drying chamber or caused by glass corrosion or 
delamination of glass.  
 
 
Fig. 3: Particle counting of MFI for a) particles ≥1 µm/ml and b) particles ≥10 µm/ml after freeze-drying 
IgG1-α: Comparing standard vials with TopLyo® vials 
 
MFI measurements showed same trend as LO measurement. Counts of particles 
≥10 µm again did not show differences between the two compared vials, whereas 
particle counts of particles ≥1 µm emphasized that TopLyo® vials are not the best 
choice for preventing IgG1-α-formulation from particle formation during freeze-drying. 
 
Concluding, particles ≥10 µm did not show any differences between TopLyo® vials 
and standard vials. MFI and LO delivered comparable results. More particles ≥1 µm 
were found in TopLyo® vials than in glass type I vials. 
Overall, standard glass type I vials are more adequate for freeze-drying IgG1-α than 
TopLyo® vials, which have more hydrophobic surfaces. Proteins can be unstable 
during freeze-drying and can unfold [Wang, 1999]. Unfolding results in presenting 
normally buried hydrophobic surfaces to the outside [Chi et al., 2003] and might lead 
to adsorption of IgG1-α-solution onto TopLyo®  vial surfaces during freeze-drying. 
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6.3.3 Zeta potential  
Zeta potential (ZP) measurements of proteins and vials deliver information about net 
charge at formulation pH [Jachimska et al., 2008; Lehermayr et al., 2011].  
We found that IgG1-α, formulated at pH 6.0, is more prone to aggregation during 
freeze-thawing in TopLyo® vials than in classic glass type I vials. 
ZP measurements of IgG1-α were not feasible in formulation used for freeze-thawing 
studies due to high ionic strength. Therefore, the IgG1-α formulation buffer was 
exchanged into 10 mM histidine buffer at pH 6.0. The pH titration (figure 4) delivers 
information about the isoelectric point with a zeta potential of 0 mV at pH 8.81. At 
formulation pH 6.0 zeta potential is +14.5 mV. 
 
Fig. 4: Zeta potential titration of IgG1-α  
 
6.3.4 Desorption of protein 
We were interested to find a further rationale to elucidate the larger amount of 
particles formed during freeze-drying the IgG1-α-formulation in TopLyo® vials.  
Adsorption of proteins on solid surfaces like glass vials is dependent from surface 
qualities like hydrophilicity and electrical state [Haynes et al., 1994]. It is described in 
literature that most protein adsorption is by non-specific binding, except at hydrophilic 
surfaces [Milthorpe, 2005]. 
Desorption of proteins adsorbed to vial surfaces delivers further information. This 
method carefully and qualitatively determines the amount of protein that is adsorbed 
to the inner vial surfaces during incubation time. The incubation time for freeze-dried 
samples is as long as the freeze-drying and reconstitution processes take. The 
references are kept in liquid state at 2-8°C. To equalize the glass contact of 
untreated references and freeze-dried samples, desorption of protein in references 
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was determined as soon as samples in lyophilisation chamber were frozen. Protein 
solutions were carefully removed from the vials.  
Protein desorption from vial surfaces is accomplished with SDS in PBS buffer at 
pH 7.2. SDS as a surfactant preserves proteins from adsorption to surfaces [Mizutani 
et al., 1978] and hence increases sample stability [Mizutani, 1980]. Further, SDS in 
running buffers leads to better resolution and increased accuracy, which is important 
in terms of analyzing very small desorbed amounts of proteins [Welling-Wester et al., 
1988]. Most importantly for these experiments, SDS at concentrations above critical 
micelle concentration (CMC) [Froeberg et al., 1999; Santos et al., 2011] has a strong 
eluting force for proteins on glass [Mizutani, 1980]. CMC of surfactants decrease with 
increasing ionic strengths, therefore reported results are consistent: The CMC of 
SDS in water was reported to be at 8.08 mM (with MSDS = 288.4 g/mol the resulting 
concentration is 0.23%) [Fuguet et al., 2005]; the CMC in PBS buffer at pH 7.2 and 
25 °C was earlier found [Mathes, 2010] at 0.94 mM (0.027%). To quantitatively 
desorb the protein from vial surfaces, a SDS concentration above CMC of 0.05 % 
was chosen for experiments. 
The desorbed protein amounts were calculated via Size-Exclusion Chromatography 
(SEC) with fluorescence detector using a 6-point calibration. Calculations were 
performed using ChemStation. 6-point calibrations from 0.0001-0.01 mg/ml for each 
protein were performed to calculate the exact amount of desorbed protein. 
Desorption amounts were related to adsorption surfaces of respective vials [mg/m²], 
listed in table 2. The adsorption surface is the contact surface from glass and IgG1-α 
solution. 
In table 2 both vial types can easily be compared directly with each other as the 
respective pairs are listed together. 
The desorbed amount of IgG1-α proved to be significantly less from standard glass 
vial surfaces than from TopLyo® vial surfaces. Obviously, a larger protein amount 
adsorbed to TopLyo® vials with hydrophobic surfaces. This could have led to the 
formation of a larger amount of protein aggregates than in classic glass type I vials. It 
is already reported in literature [Bee et al., 2011] that adsorption to interfaces can 
cause protein aggregation.  
Proteins exist in equilibrium state of folded and unfolded protein molecules [Wang et 
al., 2010]. The unfolded molecules can present their lipophilic residues, which are 
buried during folded state, to the outer face. The lipophilic residues then can adsorb 
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to surfaces, shifting the equilibrium towards unfolded molecules. The more 
hydrophobic the surfaces are the more likely unfolded protein molecules can adsorb. 
During freeze-drying proteins might be detached from those surfaces due to e.g. pH-
shifts [Norde et al., 1986]. The unfolded proteins then can form aggregates with each 
other [Brange, 2000]. Understandably, a high adsorption amount can lead to a higher 
amount of protein aggregates.  
Interestingly, larger protein amounts has been desorbed from reference TopLyo® 
vials than from freeze-dried sample in TopLyo® vials. Obviously, during freeze-drying 
the protein has been detached from vial surfaces, although proteins can adsorb 
irreversibly and in a native state [Hoehne et al., 2010]. The detached and possibly 
unfolded [Chi et al., 2003] protein could easily form aggregates. In classic glass type I 
vials the amount of desorbed protein in reference and in freeze-dried samples is 
equal (~4.8 mg/m2). This points to the fact that during freeze-drying the adsorbed 
protein is not detached from classic glass type I vials and therefore does not from as 
much aggregates as found after freeze-drying in TopLyo® vials. 
 
Table 2: Desorption of proteins from vial surfaces (n=3) 
        
Desorption 
[mg/m²] 
Standard- 
deviation 
IgG1-α TopLyo® reference 8,420 0,551 
IgG1-α Standard glass reference 4,825 0,310 
IgG1-α TopLyo® freeze-dried  7,118 0,840 
IgG1-α Standard glass freeze-dried  4,879 0,487 
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6.4 Conclusion 
This study aimed to assess the hydrophobically coated TopLyo® vials with regard to 
formation of particulate matter during freeze-drying of one model protein. TopLyo® 
vials were compared with classic glass type I vials. 
In hydrophobically coated TopLyo® vials the particle counts for all particle size 
classes were significantly higher than in standard glass type I vials.  
It was found that particle formation during freeze-drying strongly depends on the 
amount of proteins adsorbed to vial surfaces. In general, low adsorption/desorption of 
protein to vial surfaces lead to less particle formation during freeze-drying.  
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7. Simulation of Stir Stress and Prediction of 
Resulting Particle Formation in IgG1-Solutions 
7.1 Introduction 
Due to the presumed correlation of immunogenicity and aggregation of protein 
pharmaceuticals [Patten et al., 2003; Rosenberg, 2006; Schellekens, 2003; 
Schellekens, 2005] the evaluation of protein aggregation and resulting particle 
formation is becoming a more and more important factor for quality of protein drug 
products [Carpenter et al., 2008; Wang, 2005]. In this thesis, it was evaluated 
whether aggregation and particle formation resulting from stir stress can be described 
and predicted by fitting data to a theoretical model and how such prediction could be 
used for process upscaling. 
One typical stress factor for biopharmaceuticals during manufacturing, storage and 
handling is mechanical stress like occurring during stirring [Kiese et al., 2008]. 
Stirring speed is a classic set parameter for mixing larger volumes of protein 
solutions and adjusting this parameter is a typical issue during upscaling in the 
course towards commercial production.  
Applying computational fluid dynamics [Sundström et al., 2010] stirring processes 
can be simulated and the stress produced by stirring can be quantified. Stress can be 
quantitatively expressed as “stress tensor” [Pa] in the liquid phase. The determination 
of a correlation between particle formation and stress tensor values was of high 
interest. In a further step, it was investigated whether prediction of particle formation 
during upscaling processes is possible. Former approaches to predict aggregation 
rates and shelf life mainly concentrated on conformational and colloidal stabilities or 
accelerated stability studies [Roberts et al., 2003; Weiss et al., 2009] or 
spectroscopic and calorimetric methods [Youssef, 2010]. 
Stirring at six different stirring speeds (150 rpm, 200 rpm, 300 rpm, 400 rpm, 500 rpm, 
and 600 rpm) was performed in three different sized containers (5 ml, 100 ml, and 
500 ml) and particle counts were determined using light obscuration. In parallel, 
stress simulations were performed using a computational fluid dynamic simulations 
software STAR-CCM+; CD Adapco, Nürnberg, Germany.  
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7.2 Experimental setup 
Stress simulations were performed at 150 rpm, 200 rpm, 300 rpm, 400 rpm, 500 rpm, 
and 600 rpm using STAR-CCM+software (CD Adapco, Nürnberg, Germany) in 5 ml, 
100 ml, 500 ml, and 5000 ml glass bottles. Container and stirrer bar dimensions, 
density and viscosity of IgG1-formulation (table 1) are needed besides stirring speed 
to accomplish simulations. Computational fluid dynamic simulations were carried out 
in STAR-CCM+ software to gain knowledge of the dependence of the stress 
distributions in the liquid phase to the rational velocity. Minimal, maximal and 
averaged stress tensor magnitudes were extracted from simulations.  
 
Table 1: Density and viscosity of liquid and gas phase 
Liquid phase: IgG1-formulation 
Density 1.0224 g/cm3 
Viscosity 1.2017 mPas 
Gas phase: Air   
Density 1.184 * 10-3 g/cm3 
Viscosity 0.01855 mPas 
 
Stirring experiments were performed in different containers (5 ml, 100 ml, and 500 ml 
glass bottles) at 150 rpm, 200 rpm, 300 rpm, 400 rpm, 500 rpm, and 600 rpm (each 
n = 3). One experiment was performed in a 5000 ml glass bottle at 400 rpm (n = 1). 
Particle counts for different particle size classes (e.g. ≥1 µm and ≥10 µm) were 
determined using classical light obscuration (LO).  
Filling volumes of glass bottles were as follows: 5 ml (filled with 5 ml protein solution), 
100 ml (filled with 40 ml), 500 ml (filled with 200 ml), and 5000 ml (filled with 2000 ml). 
The magnitudes of the stress tensors from simulations and particle counts from 
laboratory experiments were plotted to find correlations between experimental and 
simulated values. 
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7.3 Results and discussion 
7.3.1 Situation for particles ≥1 µm 
In a first approach IgG1-solution in histidine buffer (5 mg/ml) at pH 6.0 was stirred at 
different stirring speeds in 5 ml vials and particle counts were taken afterwards. In 
parallel, applied stress on the IgG1-formulation during the stirring experiments was 
simulated by Computational Fluid Dynamics (CFD) and stress tensor magnitudes 
(minimal, maximal and averaged) were extracted. For this purpose, a virtual mesh is 
built and laid over vial dimensions and the stress tensor is calculated for each cuboid. 
The minimal and maximal stress tensors are easily extracted; the averaged stress 
tensor is calculated by the software relating to the total volume of the cuboids.  
A quasi-linear correlation between averaged stress tensor and stirring speed could 
be detected (figure 1, continuous line). Additionally, particle counts for particles 
≥1 µm correlated linearly with averaged stress tensors (figure 2, continuous line).  
As no linear dependencies of particle formation and minimal or maximal stress tensor 
were found (data not shown), we concentrated on averaged stress tensor for further 
correlations. 
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Fig. 1: Averaged stress tensor [Pa] extracted from stirring simulations in different containers over stirring 
speed 
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We were interested whether the averaged stress tensor during stirring would be 
predictable for upscaling. IgG1-solution was stirred at different stirring speeds in 
100 ml and 500 ml glass containers and applied stress during stirring on the IgG1-
solution was simulated using CFD; stress tensor magnitudes [Pa] were extracted. 
Linear correlations of averaged stress tensor and stirring speed were found (figure 1, 
dotted and dashed lines). The averaged stress tensor is linearly and almost 
congruently increasing over increasing stirring speed, independent of container size. 
This leads to the conclusion that the applied stress is similar at the same stirring 
speed in all tested containers. 
 
To find out whether also particle formation during stirring would be predictable for 
upscaling, stirring experiments were performed; particle counts were taken and 
correlated with averaged stress tensor magnitude. Experiments resulted in linear 
increases of particle counts for particles ≥1 µm over averaged stress tensor in all 
container sizes (figure 2). However, the slopes are not parallel, the same stress 
tensor did not result in the same particle count. Particle numbers are larger in smaller 
containers and filling volumes after stirring.  
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Fig. 2: Particles ≥1 µm found in different bottle sizes at different quantities of stress: linear increase of 
particle formation over increasing stir stress 
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Fig. 3: Particle count found in different bottle sizes at different quantities of stress after including the 
factor of volumes and air-/ glass-interfaces with samples (equation 3): linearity and parallelism 
 
 
The fact that fewer particles are formed in larger container sizes during stirring might 
be due to smaller surface exposure of IgG1-molecules to container surfaces and 
water and air surfaces (equation 1) [Bee et al., 2009; Bee et al., 2010; Chang et al., 
1996; Maa et al., 1997]. The larger the container, the smaller the surfaces compared 
to the containing volume. 
 
)(**2 rhrsurfaces += π  Equation 1 
hrvolume ** 2π=  Equation 2 
p
rhr
hrf *
)(**2
** 2
+
=
π
π
 Equation 3, 
whereas p = particle counts for particles >1 µm 
 
It is plausible that a smaller container surface leads to less adsorption [Baszkin et al., 
2001; Chang et al., 2005] and particle formation. Considering total filling volume and 
respective interfaces with container walls and air, particle generation and stress 
tensor correlate with the same slope for all three container sizes (figure 3 and 
equation 3). 
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When applying the STAR CCM+ software information about filling volume and vessel 
dimensions are requested. However, obviously STAR CCM+ is not adequately 
accounting for ratio of filling volume and interfaces. Particle counts are resulting from 
many factors, including ratio of filling volume and interfaces. And considering this 
factor, graphs are found to be nearly parallel (figure 3). The fact that the graphs are 
shifted parallel indicates that there is another factor influencing particle formation. On 
the one hand, the particle formation of particles ≥1 µm is controlled by the stirring 
speed, on the other hand the particle formation is influenced by the particle 
degradation of larger particles into smaller ones (see 7.3.2). 
7.3.2 Situation for particles ≥10 µm 
Interestingly, in contrast to the situation for smaller particles (≥1 µm), formation of 
particles ≥10 µm decreased with increasing stirring speed (figure 4).  
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Fig. 4: Number of particles ≥10 µm decrease over increasing stirring speed; example 5 ml vials 
 
To investigate if larger particles would be reduced in size by stirring with increasing 
speed, a different experimental approach was applied. Particles ≥10 µm were 
generated by applying freeze-thaw stress to the IgG1-solution [Hawe et al., 2009]. 
Afterwards samples were stirred using different stirring speeds. The particle number 
after stirring was inversely correlated to stirring speed (figure 5). 
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Fig. 5: IgG1 particles ≥10 µm were generated by freeze-thaw stress and reduced by stir stress 
 
Obviously, stirring stress can reduce the number of larger particles when they were 
generated by freeze-thawing.  
A model assuming a linear or exponential steady relation between particle number 
and stress tensor is valid for small particles (≥1 µm) but not for larger particles where 
the situation is more complex.  
7.3.3 Upscaling experiment 
Due to shortage of protein material only one further upscaling laboratory experiment 
in the 5000 ml bottle was performed at 400 rpm, whereas simulations of stir stress in 
the 5000 ml bottle were performed using CFD at all stirring speeds (150 rpm, 
200 rpm, 300 rpm, 400 rpm, 500 rpm, and 600 rpm).  
Simulating the stir stress in 5000 ml bottle with 2000 ml filling volume resulted in 
smaller stress tensor values as found for smaller containers at same stirring speeds 
(figure 1). Still, linear dependencies were found for stirring speed and averaged 
stress tensor. However, simulations showed that stress caused by stirring is less in 
5000 ml bottle (figure 1, dashed-dotted line): Obviously, average Stress Tensor 
Magnitude is slightly decreasing over increasing bottle size.  
The stir stress simulations revealed an average stress tensor of 0.0621 Pa during 
stirring 2000 ml IgG1-solution at 400 rpm in a 5000 ml bottle (figure 1).  
To prove the theory, that particle formation at same stirring speed is reduced in larger 
containers, not more than 8000 particles ≥1 µm/ml should be found for 0.0621 Pa stir 
stress in the laboratory experiment (compare figure 2). However, 15000 particles 
≥1 µm/ml were found. With this experiment a correlation between stress tensor and 
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particle count could not be proven. However, we only performed one experiment 
(n = 1) at one stirring speed.  
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7.4 Conclusion 
Simulations of stir stress in lab scale sized containers (5 ml, 100 ml, and 500 ml) 
provided almost same dependencies of averaged stress tensor and stirring speed 
(figure 3). Further, particle formation for particles ≥1 µm was found to increase 
linearly over increasing stirring speed/stress and decrease with increasing vessel 
size due to larger volume/surface ratios (figure 4).  
Summarizing, particle formation of particles ≥1 µm is linearly dependent to stress 
tensor magnitudes, whereas for larger particles ≥10 µm the situation is more complex. 
Nucleation and particle generation and consecutive particle growth run in parallel with 
particle degradation of larger particles during stirring. 
Prediction of particle formation for lab scale experiments is possible; however, 
relevant and interesting prediction of particle formation during upscaling into larger 
containers is not possible with the applied model software STAR CCM+. Vessel and 
stirrer bar sizes are requested when performing stir simulations, however, 
volume/surface ratios are not adequately taken into account and particle formation is 
definitely influenced by exposure to surfaces.   
STAR CCM+ simulation software is not adapted for protein solutions as 
physicochemical properties of proteins are not considered [Caflisch, 2006].  
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8. Final Summary of the thesis 
8.1.1 Relevance of submicron particle counting 
The relevance of submicron particle counting in pharmaceutical protein solutions is 
discussed controversially within the scientific community. The presence of protein 
aggregates of all sizes jeopardizes the pharmaceutical quality and safety of 
parenteral products. Blood vessel occlusions and immune system reactions are the 
most critical adverse effects with regard to protein aggregates. Pharmacopoeias have 
set limits for the presence of subvisible particles in parenterals ≥10 µm and ≥25 µm 
to be counted with light obscuration or microscopic methods. However, there is 
reason to think that these size limitations are too insensitive, as proteins are usually 
not very stable and tend to form aggregates. Further, it is known that large protein 
aggregates can grow from smaller aggregates. There is a huge risk that a lot of 
particles < 10 µm or even <1 µm are overlooked whose effect is not finally known.  
A new particle counter, the AccuSizer FY nano® marketed with a detection and 
counting limit of 150 nm to 10 µm was compared to classical methods. The 
AccuSizer would perfectly close the gap in particle detection in parenterals as particle 
counting is currently only possible for particles ≥1 µm. However, experiments showed 
that counting is only meaningful with the AccuSizer® for particles ≥750 nm. Indeed, 
the AccuSizer® is detecting particles <750 nm; however the background noise is too 
high to detect beginning aggregation or changes in particle count. The AccuSizer® 
has two detectors: a light scattering (LS) detector that captures the light intensities of 
particles from 150 –610 nm and a classical light obscuration (LO) for particles 
>610 nm. The results of our studies showed that the LS detector is not appropriate 
for counting protein particles, whereas the LO detector performs as reliable as 
classical LO instruments. Additionally, the AccuSizer® has an autodilution tool. 
Samples are diluted automatically until a given particle concentration is reached. 
However, dilution of aggregated protein samples can lead to artifacts. Aggregates 
can be redissolved and measurements can lead to false negative results or dilution 
with the wrong medium can even foster aggregation. All in all, the AccuSizer® did not 
close the gap in analytical methods.  
To study the relevance of counting submicron particles, four proteins were stressed 
mechanically, thermally and by freeze-thawing. During stress, samples were taken 
and analyzed with the new AccuSizer® FY nano (AS) and classical methods (Light 
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Obscuration (LO), Dynamic Light Scattering (DLS), Size-exclusion Chromatography 
(SEC), Microflow Imaging (MFI) and optical density measurements at 550 nm (OD)). 
Analytical results (e.g. particle counts or monomer decrease) of each method were 
plotted over time and the “points of detection” were determined. The “point of 
detection” was defined as time point, where e.g. protein aggregates increases and/or 
protein monomer decreases significantly. The comparison of the “points of detection” 
of each method and protein were used to draw conclusions regarding the relevance 
of submicron particle counting. 
Studying the relevance of submicron particle counting revealed that protein 
aggregates after mechanical stress and freeze-thawing can be detected well with 
particle counting methods, whereas protein aggregates formed during thermal stress 
are hardly detectable. Already very early SEC detects changes in thermally stressed 
samples, whereas aggregates formed during mechanical stress or freeze-thawing 
can not be detected chromatographically. Thermal stress leads to structural changes, 
whereas shaking or freeze-thawing leads to interfacial adsorption or unfolding and 
aggregation. 
Furthermore, “points of detection” of particle size classes of particles ≥1 µm and 
≥10 µm were compared regarding their sensitivity to detect changes. As protein 
aggregation is reported to start with small nuclei which grow into larger aggregates, a 
particle count increase during stress should be detected first with particle size class 
≥1 µm, then particle size classes ≥10 µm should be increasing. Our studies 
confirmed this aggregation theory. Indeed, particles ≥1 µm increased earlier during 
stressing process than particles ≥10 µm in 6 of 12 cases. However, the difference 
was not always given, and in 2 of 12 cases even particles ≥10 µm increased before 
particles ≥1 µm.  
Microflow ImagingTM (MFI) is also a particle counting instrument with a working range 
of 1-100 µm. MFI combines digital microscopy, micro-fluidics, and image processing. 
Besides particle count and size, MFI delivers information about form, translucency, or 
morphologic properties. For detection with MFI, a smaller refractive index difference 
between particles and fluid is required as e.g. for detection with LO, giving higher 
particle counts when aggregates were very translucent. We also assessed MFI with 
regards to ability of early and sensitive protein aggregate detection. Results showed 
that MFI indeed deliver slightly more information than classical LO: particles formed 
during mechanical or freeze-thaw stress are earlier detectable with MFI. Protein 
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particles that are not translucent but dense are detected as well as with LO. 
Polysorbate 80 (PS-80) can play a role regarding the appearance of particles. IgG1 
particles formed during mechanical or freeze-thaw stress under PS-80 protection are 
found to be consistently dark and detectable with LO, whereas protein particles 
generated in formulations without PS-80 protection can be translucent and only 
detectable with MFI.  
For the time being, it is recommended to use SEC and LO for particles Nr.10 µm (as 
required in regulatory guidelines) to cover the particle formation after common 
stresses. Assessing a sample with SEC and LO allows a sensitive analytic . However, 
regulatory guidelines should be amended: Including particle counting of particles 
Nr.1 µm using MFI as a new particle counter is very helpful and informative regarding 
the assessment of protein particles and their appearance.  
8.1.2 Particulate matter in serum solutions 
Protein aggregation is discussed controversially, however only recently the 
discussions received a new impulse towards in vivo experiments. Many studies have 
been performed observing the protein particles in vitro. However, it is much more 
important to learn about the fate of accidently aggregated proteins in vivo. In our 
studies a first approach in this direction has been made. Protein particles are 
incubated in serum mimicking solution and particles were counted. We were 
interested, whether protein aggregates dissolve or rather grow fast due to further 
adsorption or aggregation.  
In our studies, three different proteins (IgG1, GCSF and rPA) were stressed 
mechanically or by freeze-thawing and diluted into serum solution, phosphate buffer 
and formulation buffers, particle counts were monitored directly after dilution and after 
20 hours.  
The results showed that protein particles of IgG1 were stable in serum solution over 
tested time, whereas GCSF and rPA particles were becoming translucent and the 
particle count increased. Translucent particles were not detectable by LO, whereas 
MFI was perfectly able to detect the less dense particles. The fact that protein particle 
counts can increase and that protein particles can become translucent is alarming, as 
particle counts within parenteral solutions are currently monitored with LO.  
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8.1.3 Effects of dilution, pH and standing time on particulate matter 
During experiments evaluating “particulate matter in serum solutions” (Chapter 8.1.2) 
decreasing particle counts were found after dilution of mechanically stressed IgG1 
into phosphate buffer. The effect of time, pH-shifts and standing time on stressed 
IgG1-formulation was monitored within these studies, particle counts were taken with 
LO and MFI. IgG1-formulation was mechanically stressed and diluted into phosphate 
buffers of different ionic strengths and pH values. 
It was found that smaller particles grow into larger ones over time, more pronounced 
at alkaline pH close to the isoelectric point (IEP at pH 8.81) and at higher buffer 
molarities. These results prove the theory that protein aggregates can grow from 
small nuclei.  
MFI-images of samples were compared regarding their intensity mean, which is 
described in illumination intensity levels. Our studies show that mean intensity 
decreases over increasing pH and also over time. Mean intensity gives information 
about the appearance of the detected particles. High intensity mean values are found 
for translucent particles at lower pH values. The more stable aggregates are, the 
denser they appear.  
8.1.4 Comparison of TopLyo® vials (Schott) with standard glass type I vials  
Primary packaging materials should be chosen carefully as they are in contact with 
protein solutions. The interactions of recently marketed hydrophobically coated 
TopLyo® vials with IgG1 are studied with regard to particulate matter. The 
hydrophobic coating is intended to minimize adhesion and interaction of substances 
and prevent the cake from collapsing. However, the hydrophobic surface might also 
exhibit the risk of protein unfolding and accompanying aggregation or adsorption. A 
connection was found between protein adsorption to vial surfaces and particle 
formation during freeze-drying processes: If reference solutions of unstressed protein 
show a higher adsorption to glass vial surfaces than freeze-dried or freeze-thawed 
samples, protein is detached during processing and protein particles are formed.  
Protein reference is IgG1-α solution filled into the glass vials to be examined and 
stored in the refrigerator. IgG1-α showed stronger adsorption to TopLyo® vials and 
corresponding high amounts of particles. 
TopLyo® vials are not the first choice for freeze-drying or freeze-thawing of an IgG1-α.  
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8.1.5 Stress simulations  
Defining the most adequate stirring speed during upscaling processes is usually a 
critical factor in protein formulation development. Computational Fluid Dynamics 
(CFD) offers the possibility to simulate stresses during stir processes. We assessed 
the possibility to predict mechanical stress during upscaling with regard to particulate 
matter. Linear dependencies of particle counts for particles ≥1 µm and stirring speed 
were found for all tested volumes. Additionally, particle formation of particles ≥1 µm is 
linearly correlated to stress tensor magnitudes. For larger particles the situation was 
more complex as nucleation and degradation during stirring run in parallel. When 
larger particles are formed they may be dispersed into smaller particles by the stirrer. 
Further, CFD does not sufficiently account for the ratio of container volume and 
surface; only after recalculation parallel dependencies are found between particle 
counts ≥1 µm and stirring speed in different containers. In summary CFD is not 
adequate to predict protein particle formation during upscaling as physicochemical 
properties are not well enough included. 
8.2 Conclusion 
Protein particle formation is a complex issue within development and manufacture of 
protein drug products. Every step and equipment has to be carefully chosen to 
minimize protein aggregation as the aim of pharmaceutical development is quality by 
design. Accidently aggregated protein drug products can cause reactions of the 
immune system. The fact that aggregates may even be growing upon administration 
in vivo has to be considered. 
The need of new pharmacopoeial methods is controversially discussed and our 
studies shall contribute to this field. On the one hand, the tested particle counters did 
not deliver reliable particle counts for the submicron range. Further, particle growths 
of particles ≥1 µm and ≥10 µm happened almost parallel. On the other hand, we 
showed that during stirring nucleation and degradation of larger particles run at the 
same time. This leads us to the proposal to monitor at least particles ≥1 µm. MFI 
proved to be an informative method to count and visualize protein particles. It is much 
more sensitive than classical LO and should be considered as a new pharmacopoeial 
method. 
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9.  Appendix 
 
To complete the data assessed in chapter 3 (Relevance of submicron particle 
counting for development and quality assurance of protein pharmaceuticals), 
following data sets are presented.  
Four proteins were stressed using three different stressing methods. Each of those 
12 experiments was attended using six instruments and methods: three particle 
counters, SEC, DLS and turbidity measurements. The particle counter data were sub 
classified into particle size classes (MFI and LO: particles ≥1.0 µm and ≥10.0 µm; 
AccuSizer: particles ≥250 nm, ≥500 nm, ≥750 nm, ≥1.0 µm, ≥2.5 µm, ≥5.0 µm and 
≥7.5 µm) to get a better overview about particle formation in those different size 
classes. In total, 14 raw data sets were obtained for each single experiment. In order 
to outline the raw data, an overview about the time points of first detection is 
presented in this appendix. The time point of first detection, marked in dark grey, is 
the point at which stress results in e.g. formation of particle or an increase of turbidity.  
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9.1 Overview tables of time points of first detection after stressing 
IgG1-α 
Table 1: Heat stress of IgG1-α; detection power of different methods (results of particle counters were 
distinguished in different size classes, n = 3) 
 
 
Table 2: Mechanical stress of IgG1-α; detection power of different methods (results of particle counters 
were distinguished in different size classes, n = 3) 
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Table 3: Freeze-thaw stress of IgG1-α; detection power of different methods (results of particle counters 
were distinguished in different size classes, n = 3) 
 
 
9.2 Overview tables of time points of detection after stressing 
IgG1-ß 
Table 4: Heat stress of IgG1-ß; detection power of different methods (results of particle counters were 
distinguished in different size classes, n = 3) 
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Table 5: Mechanical stress of IgG1-ß; detection power of different methods (results of particle counters 
were distinguished in different size classes, n = 3) 
 
 
Table 6: Freeze-thaw stress of IgG1-ß; detection power of different methods (results of particle counters 
were distinguished in different size classes, n = 3) 
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9.3 Overview tables of time points of detection after stressing 
GCSF 
Table 7: Heat stress of GCSF; detection power of different methods (results of particle counters were 
distinguished in different size classes, n = 3) 
 
 
Table 8: Mechanical stress of GCSF; detection power of different methods (results of particle counters 
were distinguished in different size classes, n = 3) 
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Table 9: Freeze-thaw stress of GCSF; detection power of different methods (results of particle counters 
were distinguished in different size classes, n = 3) 
 
 
9.4 Overview tables of time points of detection after stressing rPA 
Table 10: Heat stress of rPA; detection power of different methods (results of particle counters were 
distinguished in different size classes, n = 3) 
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Table 11: Mechanical stress of rPA; detection power of different methods (results of particle counters 
were distinguished in different size classes, n = 3) 
 
 
Table 12: Freeze-thaw stress of rPA; detection power of different methods (results of particle counters 
were distinguished in different size classes, n = 3) 
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